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Hair loss (alopecia) is one of the most feared side effects of chemotherapy.(1-4) About 
one quarter of patients with cancer is at risk for chemotherapy-induced alopecia 
(CIA).(5) This also applies to men, although this is often not discussed.(6) Whereas 
about 80% of patients considers CIA as an important side effect, (7) clinical research has 
shown that the impact of CIA is underestimated by both oncologists and nurses.(8-11) 
Up to now, scalp cooling is the only method to prevent CIA. When using  
scalp cooling, a cold liquid is pumped through a cap which is placed on the head of the 
patient before, during and after intravenous treatment with chemotherapy. It is 
hypothesized that this causes subcutaneous vasoconstriction resulting in reduced 
perfusion of cytostatic drugs to the hair follicles and a reduction of biochemical activity. 
During the San Antonio Breast Cancer symposium in December 2016, the results of the 
randomized SCALP trial were presented. This randomized clinical trial assessed whether a 
scalp cooling device was effective in reducing CIA. The results showed that scalp cooling 
was safe and effective in 50.5% of patients.(12) Following this and another publication in 
JAMA(13), scalp cooling has been approved for cancer patients with solid tumors by the 
FDA in the United States.(12,13) A poll at the St. Gallen International Breast Cancer 
Conference in March 2017 showed that 83% of the participants felt that scalp cooling was 
a good option to prevent hair loss during (neo) adjuvant chemotherapy. 
At present, scalp cooling is available in almost all hospitals in the Netherlands.  
It is frequently used in women with breast cancer receiving chemotherapy, but also in 
women with other tumor types and in men with prostate cancer receiving docetaxel. This 
introduction provides an overview of the main points of interest when scalp cooling is 
applied in clinical practice. 
 
The hair cycle and p53 mechanism in CIA 
Under normal circumstances, the growth cycle of a hair follicle consists of three main 
phases: the anagen, catagen and telogen phase.(14) The active growth (anagen) phase 
lasts for three to seven years and involves the growth of a hair from a hair follicle. During 
the transition (catagen) phase (2-3 weeks), the hair stops growing and releases itself 
from the blood supply. During the resting (telogen) phase (3-4 months), the hair stays 
attached to the hair follicle and does not grow. When the old hair is shed, the telogen 




Figure 1: Hair cycle. Adapted from: Drug discovery for alopecia: gone today, hair tomorrow. Santos et al. 
Expert Opin Drug Discov. 2015;10(3):269-292.(15) 
 
Since 90% of all hair is in anagen phase and rapidly proliferates, hair follicles are highly 
at risk to be affected by chemotherapy, resulting in CIA.(16,17) Hair shaft shedding 
begins days to weeks after the initiation of chemotherapy. The exact mechanism is not 
completely understood, but it is known that regression of the hair follicle activates a 
variety of signaling pathways, which induce apoptosis.(18) Although the role of many 
molecular factors in the DNA-damage response remain to be explained, P53, a key 
mediator of cellular mechanism of stress response, has a crucial role in the occurrence of 
apoptosis.(16) (Figure 2) In a mouse model for CIA, Botchkarev demonstrated that p53 
is essential in this process. Administration of cyclophosphamide was associated with rapid 
increase of p53 concentrations in hair-matrix keratinocytes, followed by apoptosis. By 




Figure 2: Apoptosis depends on p53. Adapted from p53 -Dependent and -Independent Nucleolar Stress 
Responses. Olausson et al. Cells. 2012 Dec; 1(4): 774–798.(19)  
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Prevention of chemotherapy induced alopecia 
Several researchers have investigated pharmacological as well as nonpharmacological 
measures to prevent CIA. Little information is available in terms of medications. At 
present, there are no approved drug treatments for preventing CIA. Minoxidil is well 
recognized to promote hair growth, but topical administration of minoxidil, as well as 
other hair growth cycle modifiers, does not prevent CIA.(14,20) Other agents with 
different action mechanisms like cytokines, growth factors, antioxidants, proliferation 
modifiers and inhibitors of apoptosis showed some effect, but only in animal CIA 
models.(14) Reliable preventive pharmacological therapy to prevent CIA in human is still 
sought. Nonpharmacological measures such as scalp tourniquets were designed to reduce 
the blood flow to scalp hair follicles during chemotherapy infusion.(2,20) However, most 
studies investigating the effect of tourniquets used inconsistent techniques and involved 
small numbers of patients. Therefore, it was difficult to determine the exact effect.(20) 
Tourniquets are no longer recommended due to patient discomfort. Currently, most 




In the Netherlands cooling machines both from Paxman (England) and from Dignitana 
(Sweden) are used. These are the two largest suppliers on the market and although both 
types of coolers differ slightly from each other, no differences in results are seen in 
practice. 
 
A           B           
Figure 3: Cooling machines from Paxman (A) and Dignitana (B) 
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Liquid circulates through the devices at a constant temperature of -10°C. For the best 
possible result, the cooling cap, which is connected to the device, must be optimally 
connected to the head. Scalp cooling is applied during the infusion of chemotherapy, with 
a pre-cooling time of 30 minutes to ensure the scalp is at the required temperature, and 
a follow-up time of usually 90 minutes.  
 
Results 
Within the literature, efficacy results for scalp cooling vary because of variability in study 
design, such as population, chemotherapy regimen, outcome measure, type of cooling 
system/device, and cooling duration.(21) In most trials, scalp cooling has shown a 
positive effect in reducing CIA following a number of different chemotherapy 
regimens.(2,12,13,22) A meta-analysis of Shin et al. in 2015 showed that the risk of hair 
loss became three times smaller due to the use of scalp cooling.(23) These results were 
confirmed in 2017 with a meta-analysis of randomized scalp cooling studies,(24,25) and 
a review of controlled clinical trials(25), which added additional support to the finding of 
statistically significant higher rates of hair preservation with scalp cooling compared to 
chemotherapy administered without cooling.  
In the Netherlands, scalp cooling has been used since 1970. A Dutch open patient 
registration study was started in 2006, in which more than 7000 patients have now been 
included. Scalp cooling results in this registry were positive for most chemotherapy 
regimens.(22) Successful scalp cooling was the patient's self-determined need to wear a 
wig or other head covering. It was concluded that results were best for monotherapy with 
low dose taxanes (95% effect) and poor in the TAC regimen, a combination 
chemotherapy with docetaxel, adriamycin and cyclophosphamide (8% effect). These 
findings are confirmed in other studies.(12,13)  
 
Factors that influence the result of scalp cooling 
The type of chemotherapy, the number of cycles, the dose, administration route and the 
speed of administration can strongly influence the result of scalp cooling.(22,26) The 
influence of all other patient-related factors (age, gender and hair type) is less convincing 
or lacking.(2,22,23,27) Factors such as liver function and menopausal status might 
influence the efficacy, but there is no convincing evidence yet.(2,22,23,27) The influence 
of the scalp skin temperature is probably the most important factor influencing the result 
of scalp cooling.(28) However, the scalp skin temperature in patients using scalp cooling 
does not always decrease to optimal temperature levels.(28,29) Both a better connection 
between the cap and the head and individual temperature adjustment could overcome 
this problem. Temperature has also been proven to be critical in in vitro research. 
Laboratory studies provided biological evidence for a positive correlation between the 
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degree of cooling and the survival of hair follicles. Al Tameemi et al. reported a study in 
which they found that lowering the temperature from 22 °C to 18 °C and even further to 
14 °C, resulted incrementally in a better degree of rescue from drug cytotoxicity. 
Cytoprotection was detectable even for the maximal drug doses tested, which had 
previously resulted in complete loss of cells.(30) Despite the increased knowledge about 
the effect of temperature on cell survival, there still is a lack of knowledge about the 
optimal temperature of scalp cooling and how to reach this. This lack of knowledge also 
applies for the post-infusion cooling time, another factor which could influence the effect 
of scalp cooling. Shortening the post-infusion cooling time from the usual 90 minutes to 
20 minutes is justified for docetaxel, but for other regimens this time is unknown and 
should be studied.(6) 
 
Tolerance 
Scalp cooling is usually well tolerated.(23,31,32) Several publications report a visual 
analogue scale (VAS) score of 6.9-8.3 (0 'not tolerable' to 10 'very well 
tolerated').(2,6,33,34) Side effects include chills, dizziness, headache, nausea and a 
sensation of cold.(12,21) However, these side effects are mild (mostly grade 1) and are 
for less than 5% of patients a reason to stop scalp cooling.(2,21-23)  
 
Safety 
The lack of safety research has limited the use of scalp cooling for years. In particular, it 
was feared that scalp cooling would protect possible occult metastases in the scalp from 
chemotherapy, with the danger of scalp metastasis. Therefore, scalp cooling is not 
recommended in patients with hematological malignancies. In one patient with leukemia 
and another patient with mycosis fungoides, who both chose to use scalp cooling, 
cutaneous disease recurred on the scalp after several years, with no other evidence of 
disease.(35,36) However, in solid tumors, there has never been evidence for the 
occurrence of scalp metastases due to scalp cooling.(2,5,23,37) Scalp metastases rarely 
appear in patients with breast cancer (0.003-3%).(5,24) This risk is not increased in 
patients who use scalp cooling (0.04-1%).(5,24) A retrospective study with 6-8 years 
follow up found no difference in the occurrence of scalp metastases between patients 
with and without scalp cooling.(38) A large study by Van den Hurk et al. with a follow-up 
of 5 years also showed no increased risk of developing scalp metastases.(22) These 
results were confirmed by a meta-analysis, performed by Rugo(24) and Shah(25) in 
2017. When scalp metastases occurred during scalp cooling in the metastasized setting, 
they always appeared simultaneously or after occurrence of metastases elsewhere.(37) 
During many years of application of scalp cooling, there has never been an adverse effect 
of scalp cooling on the disease. 
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The risk of possible metastases in the skull or even in the brain is very unlikely. 
Research has shown that there is no or only a minimal decrease in temperature both in 
the skull and in the brain.(39) 
Scalp cooling is contraindicated in patients who suffer from cold sensitivity, cold 
agglutinin disease, cryoglobulinaemia, cryofibrinogenaemia or cold posttraumatic 
dystrophy. 
  
Developments and recommendations 
The use of scalp cooling in oncology patients treated with chemotherapy in the 
Netherlands is still low (29%).(7) There are large differences in the supply of scalp 
cooling between hospitals and sometimes scalp cooling is not used in (neo)adjuvant 
chemotherapy regimens. This limited application lies both in the limited supply and the 
limited demand. Only 30% of potential candidates for scalp cooling is aware of the 
existence of scalp cooling. (Multiscope, personal communication, 2016-2017) 
Offering the possibility of scalp cooling largely depends on the opinion of doctors 
and nurses on the efficacy of scalp cooling to prevent CIA.(40) As a result, there are 
large differences in the availability of scalp cooling for men and women, for different age 
groups and for different types of chemotherapy. In addition, the administration of scalp 
cooling is often limited because of staff shortages or logistical problems. 
Given their role in the use of scalp cooling, nurses are perhaps best equipped to 
inform patients about scalp cooling. Together with oncologists and managers, 
preconditions such as training and extra time could be created, so that every patient with 
a desire to try scalp cooling can be informed and given the opportunity to use it. 
It appears that the knowledge on CIA and scalp cooling is evolving slowly, but it is 
expected that this will change due to the breakthrough of scalp cooling in the USA. 
Further research should focus on improving the results of scalp cooling and on 
personalizing scalp cooling. In addition, implementation of scalp cooling should be 
included in (international) oncology guidelines. 
 
OBJECTIVES AND OUTLINE OF THIS THESIS 
The aim of this thesis was to study the mechanism of scalp cooling in patients treated 
with chemotherapy and to refine and personalize the technique. 
 
In chapter 2 we examine various factors influencing the effectiveness of scalp cooling in 
the prevention of chemotherapy-induced alopecia and provide a critical appraisal of  
clinical studies.  
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In chapter 3 we discuss the relation between scalp skin temperature and the efficacy of 
scalp cooling. Apart from the type or dose of chemotherapy, as described in chapter 2, 
the scalp skin temperature during scalp cooling is a very important factor to prevent hair 
loss. To obtain optimal results, we analysed which threshold should be reached below 
which hair loss can be prevented.  
 
In chapters 4 and 5 we compared different post-infusion scalp cooling times to 
investigate its effect on the outcome of scalp cooling. The duration of post-infusion 
cooling implies a prolonged stay on the chemotherapy ward, which is potentially a 
disadvantage both for patients and for the logistics of the clinic. Chapter 4 describes a 
shorter post-infusion time in the low dose docetaxel chemotherapy regimen, in which 
cooling is very effective. On the other hand, scalp cooling is also offered in regimens with 
a more limited effect. Therefore, a prolonging of the post-infusion cooling time was 
investigated in an anthracycline containing chemotherapy regimen. Chapter 5 presents 
the results of a randomized study, investigating a longer post-infusion scalp cooling time.  
 
In chapter 6 the various methods used to evaluate the outcome of scalp cooling are 
assessed. In this study the common subjective methods to evaluate hair loss were 
compared with a new objective method in order to standardize the measurement of hair 
loss in clinical trials. Standardization of measurement would simplify the evaluation and 
comparison of potential therapies to prevent CIA. 
 
In chapter 7 we explored molecular damage-response pathways in hair follicles from 
patients treated with chemotherapy, to provide a better understanding of the scalp 
cooling working mechanism. Investigating hair follicles of patients treated with 
chemotherapy, is the only way to demonstrate the working mechanism of scalp cooling 
and to explain why scalp cooling works in one patient, but not in the other. 
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ABSTRACT 
Introduction: The success of scalp cooling in preventing or reducing chemotherapy 
induced alopecia (CIA) is highly variable between patients and chemotherapy regimens. 
The outcome of hair preservation is often unpredictable and depends on various factors.  
Methods: We performed a structured search of literature published from 1970 till 
February 2012 for articles which reported on factors influencing the effectiveness of scalp 
cooling to prevent CIA in cancer patients.  
Results: Literature search identified 192 reports of which 32 studies were considered 
relevant. Randomised studies on scalp cooling are scarce and there is hardly information 
on the determinants of the result. Hair preserving results of scalp cooling depend at least 
on dose and type of chemotherapy, with less favourable results at higher doses. 
Temperature seems to be an important determinant. Various studies suggest that a 
subcutaneous scalp temperature below 22°C is required for hair preservation.   
Conclusions: The hair preserving results of scalp cooling are variable and mainly depend 
on type and dose of chemotherapy and probably on degree and duration of cooling.   
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INTRODUCTION 
Chemotherapy induced alopecia (CIA), although being reversible, is for patients one of 
the most distressing side-effects. It has psycho-social implications and may affect body 
image and acceptance of treatment.(1-5) For some patients CIA is a reason to refuse 
chemotherapy, and up to 8% of patients may choose less effective chemotherapy 
regimens if these regimens do not cause hair loss.(6;7) 
In healthy persons, scalp hair follicles show a pattern of cyclic activity. The hair 
growth (anagen) phase involves the growth of a hair from a hair follicle and lasts for 
three to seven years. During the transitional (catagen) phase, the hair follicle atrophies 
and migrates upwards to a resting level in the skin. During the resting (telogen) phase, 
the hair does not grow but stays attached to the hair follicle. The telogen phase ends 
when the old hair is shed and a new hair is regenerated in the anagen phase. In the adult 
scalp, approximately 90% of the follicles is in the growth phase.(8;9)   
Chemotherapy acts on rapidly growing cells including hair follicles and 
chemotherapy induced shedding of hairs usually occurs seven to fourteen days after 
infusion.(8;10) The incidence and severity of alopecia depends both on the type (table 1) 
as well as the dose of chemotherapy.(6;9;11-13) Apart from hair loss from the scalp, 
patients may also  loose their eyebrows, eyelashes and pubic hair after several cycles of 
chemotherapy. Although alopecia  is a reversible side effect, permanent alopecia has 
been reported incidentally after high dose chemotherapy.(10)  
 







Bortezomib Bleomycin Busulfan 
Cabazitaxel Cyclophosphamide Docetaxel 
Carboplatine Epirubicin Doxorubicin 
Catumaxumab Trastuzumab Etoposide 
Cisplatin Panitumumab Gemcitabine 
Cytarabin  Idarubicin 
Dactinomycin  Ifosfamide 
Ixabepilone  Irinotecan 
Lomustine  Mitomycine 
Methotrexaat  Oxaliplatin 
Pemetrexed  Paclitaxel 
  Topotecan 
  Vinorelbine 
  Procarbazine 
Source: Investigator brochures 
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Since the 1970s, scalp cooling is being used to reduce and prevent CIA.(14) It 
reduces skin temperature, thereby affecting the exposure and metabolism of cytotoxic 
agents in the hair follicles. However, the effectiveness of scalp cooling in preventing 
alopecia is highly variable and unpredictable. We therefore wanted to explore possible 
reasons why scalp cooling works in one patient but fails in another. 
  
MATERIALS AND METHODS 
We designed a search strategy to identify relevant literature that described the use of 
scalp cooling in preventing chemotherapy induced hair loss among patients treated for 
cancer. We performed our search on February 24, 2012 in the electronic databases 
PubMed, Embase, and the Cumulative Index to Nursing and Allied Health Literature 
(CINAHL) for literature published from 1970 through February 24, 2012, linking the 
subject search headings with text word and MESH terms.  
A combination of the following search terms was used: ((("chemotherapy"[all 
fields] OR "antineoplastic protocols"[Mesh] OR "antineoplastic agents"[Mesh] OR 
"neoplasms/drug therapy"[Mesh Terms] OR "chemotherapy-induced"[all fields])  AND 
("hair loss"[all fields] OR "alopecia"[Mesh] OR "alopecia"[all fields])) OR 
"alopecia/chemically induced"[Mesh Terms]) AND ("scalp cooling"[all fields] OR "scalp 
hypothermia" OR "cold cap"[all fields] OR ("hypothermia, induced"[Mesh] AND 
("scalp"[Mesh] OR "scalp"[all fields]))) 
We did not restrict the search strategy to a particular type of study design.  
Articles were selected if they assessed any possible factors affecting the 
effectiveness of scalp cooling in preventing alopecia after chemotherapy. Only full text 
articles in English and Dutch were considered. We also did a manual search for any 
relevant references used in the articles found. Papers that described scalp cooling as a 
safety issue or focussed solely on impact or tolerance were excluded.  
 
RESULTS 
The initial search resulted in a total of 192 citations (76 Hits in PubMed, 92 in Embase, 
and 24 in CINAHL). After removing duplicates, 102 citations remained; 70 were discarded 
based on title or abstract because they did not meet the inclusion criteria and the 32 
citations that were considered relevant, were included in this review (table 2). A manual 
search of references in the relevant articles did not yield any additional study. The 
majority of the articles (20 out of 32) was published between 1980 and 2000. Since 
2010, only 3 articles have been published on possible factors influencing the 
effectiveness of scalp cooling in the prevention of CIA. Excluding one large multicenter 
observational study (ref 14), the median number of reported patients was 35 (range 9-
180).  
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Table 2. Factors influencing the result of chemotherapy induced alopecia 















1 Anderson 1981 31   X  
2 Hunt 1982 22  X X X 
3 Guy 1982 12    X 
4 Gregory 1982 24   X  
5 Dean 1983 33   X X 
6 Wheelock 1984 11  X X  
7 Satterwhite 1984 26  X X  
8 Vendelbo 1985 61   X  
9 Middleton 1985 60   X X 
10 Bulow 1985 10   X  
11 Symonds 1986 26   X X 
12 Robinson 1987 32   X  
13 David 1987 180   X  
14 Giaccone 1988 39  X   
15 Hillen 1990 48   X X 
16 Adams 1992 34  X X  
17 Tollenaar 1994 35  X X  
18 Lemenager 1997 98  X X X 
19 Peck 2000 10    X 
20 Katsimbri 2000 70   X X 
21 Christodoulou 2002 83   X X 
22 Ridderheim 2003 74   X X 
23 Macduff 2003 40   X X 
24 Massey 2004 94   X  
25 Grevelman 2005 Review   X  
26 Janssen 2005 Model X  X  
27 Janssen 2007 9   X  
28 Auvinen 2010 64  X X  
29 Komen 2011 27   X  
30 Kargar 2011 63   X X 
31 Van den Hurk 2012 76   X  






The effectiveness of scalp cooling in cancer patients depends on many factors, 
which can be related to patient characteristics, chemotherapy characteristics and the 
procedure of scalp cooling (table 2). Only one study reported on a relationship between 
patient characteristics and scalp cooling effectiveness, while in 9 articles various 




In a large multicenter observational study in the Netherlands Van den Hurk et al.(15) 
concluded that scalp cooling was more effective at younger age, in male patients and in 
patients with a Caucasian type of hair. In a computer model study, Janssen et al.(16) 
found that the thickness of the hair layer correlated with the scalp skin temperature 
during scalp cooling. This may explain the lower effectiveness of scalp cooling in patients 
with Afro hair, who have a thick layer of hair which acts as an insulating layer between 
the cooling cap and the scalp.  
 
Chemotherapy characteristics 
Type and dose 
The incidence and severity of CIA using scalp cooling depends on the type and dose of 
chemotherapy.(1;1;2;12;15;17-22) Only three of these reported studies randomised 
patients to chemotherapy either with or without scalp cooling. Therefore, results of 
effectiveness of scalp cooling have to be compared with historical series with identical 
chemotherapy regimens. An ongoing Dutch observational study collects data on the 
effectiveness of scalp cooling with various types and doses of chemotherapy regimens 
(table 3)(15) For anthracycline containing regimens, a higher dose of anthracycline was 
correlated with a worse outcome of scalp cooling. (15;17) With 5-Fluorouracil-Epirubicin-
Cyclophosphamide (FEC) chemotherapy, 33% of the patients treated with epirubicin at a 
dose of 100 mg/m2 did not require a head cover versus 52% of the patients treated with 
epirubicin at a dose of 90 mg/m2. Likewise, 59% of the patients treated with docetaxel at 
a dose of 100 mg/m2 did not require a head cover versus 79% of the patients treated at 
a dose of 75 mg/m2 (table 3).(15) Of notice, scalp cooling failed to prevent alopecia in 
most patients who were treated with the combination of docetaxel, adriamycin, 
cyclophosphamide (TAC) chemotherapy for early breast cancer. 
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Table 3. Overview of scalp cooling results in The Netherlands 2006-2009 
Indication and chemotherapy type(1) Total number of 
patients using scalp 
cooling  
% patients not 
wearing a wig or 
head cover 
Breast cancer    
FEC-T (500/100/500-100)2 45 47 
FEC (500/100/500) 123 33 
FEC (500/90/500) 552 52 
FAC (500/50/500) 38 55 
P (70-90) (mono/combinations)3 39 82 
T (100) (mono/combinations)4 42 59 
T (75) (mono/combinations)4 58 79 
TAC (75/50/500)5 66 8 
AC-TH (60/600-100)2 16 63 
AC-PH (60/600-175) 21 29 
AC-PH (60/600-80) 29 48 
AC (60/600) 74 39 
Ovarian cancer   
P-Carbo(175-5/6) 49 37 
Colon cancer   
Irinotecan (350) 41 29 
1Dosage in mg/m2 
2Sequentially: FEC followed by T/ AC followed by T or P and H 
3Weekly schedule 
4Docetaxel combinatons with exception of docetaxel/adriamycine/cyclofosfamide (TAC) 
5T,A en C simultaneously 
C: Cyclofosfamide; Carbo: Carboplatin; A: Adriamycine; T: Docetaxel; E: Epirubicine; F: 5-fluorouracil; H: 
Herceptin (trastuzumab); P: Paclitaxel 
Source: Breed W, van den Hurk CJ, Peerbooms M. Presentation, impact and prevention of chemotherapy 
induced hair loss: scalp cooling potentials and limitations: dermatology 2011; 6: 109-125 
 
Liver function 
According to several studies, scalp cooling does not prevent CIA in most patients with 
biochemical evidence of abnormal liver function.(2;23-27) This may be predicted on the 
basis of pharmacokinetics of chemotherapy that is metabolized by the liver. For these 
drugs, an impaired liver function is associated with higher and more prolonged plasma 
concentrations.(23) In contrast, Grevelman et al.(11) concluded that in only six out of 13 
studies, impaired liver function seemed to be related to less benefit from scalp 
cooling.(11) In these studies patients were treated with doxorubicin or epirubicin. 
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Scalp cooling characteristics 
Temperature 
It is evident that optimal fitting of the cold cap is an important factor for success. Bald 
areas are seen where the cap did not fit properly (figure 1). Contact between the cold 
cap and the scalp skin is decisive for lowering the skin temperature.(16) In 1982, 
Gregory et al.(28) found a relation between the degree of decrease in scalp skin 
temperature and the protective effect of scalp cooling against hair Ioss in patients 
treated with doxorubicin. They concluded that to prevent CIA the subcutaneous scalp 
skin temperature should be reduced below 22ºC corresponding to an epicutaneous scalp 
temperature below 19ºC to prevent CIA .(29) Hillen et al.(30) attributed the success of 
their air-cooling methods in part to achieving epicutaneous scalp temperatures below 
15ºC and Bülow reported that in two out of ten healthy volunteers it was impossible to 
obtain a subcutaneous scalp temperature below 28ºC, which is in agreement with the 
findings of Gregory and Janssen and implies that some persons consistently respond to 
scalp cooling with only a minor reduction in subcutaneous temperature.(28;29;31) As 
these studies used different and obsolete scalp cooling techniques and report different 
cut-off levels of scalp skin temperature, a study on scalp temperature using the modern 
Paxman® system is presently being done at our centre. Janssen demonstrated that 
wetting the hair increased the conductivity of the hair layer, resulting in a further 
decrease in scalp skin temperature.(16) However, there are no randomized studies 
regarding the influence of wetting on scalp skin temperature and scalp cooling success 
rates, while wetting the hair increases the burden for the patient. 
 
Figure 1. Bald areas are seen where the cold cap did not fit properly 
   
 
Perfusion 
To gain more insight into the effect of cooling, Janssen et al. studied the relationship 
between skin temperature and skin perfusion during a cooling experiment in 9 healthy 
subjects.(16) During scalp cooling, relative perfusion of the scalp skin gradually dropped 
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down to 28%. A plateau in perfusion was reached after prolonged cooling to lower skin 
temperatures. This reduction in perfusion was in line with the findings of Bülow(29) and 
Hillen(30), who found that blood flow during scalp cooling was reduced to 25% of the 
basal value. Bülow also stated that blood flow was not reduced any further when the 
subcutaneous scalp temperature was below 30ºC.(29)  
  
Scalp cooling time 
The duration of scalp cooling might influence the hair protective effect of scalp cooling. In 
most studies the pre-cooling time (time between start of scalp cooling and start of 
intravenous infusion of chemotherapy) ranged from 5 to 30 minutes.(12;17-23;25-
27;30;32-37) At the Medical Centre Alkmaar we have measured serial scalp skin 
temperatures during scalp cooling in healthy subjects and patients to determine the 
optimal pre-infusion cooling time. In 27 persons treated with scalp cooling using the 
Paxman® PSC1 system, scalp temperature reached a constant level of approximately 
18ºC after 45 minutes. These preliminary data suggest that as no further reduction in 
temperature occurred, a pre-infusion cooling time of 45 minutes seems optimal when a 
non pre-cooled cap is used.(38) 
While the pre-infusion cooling time is well known, there is much uncertainty about the 
post-infusion cooling time. Theoretically, the cooling period after infusion of 
chemotherapy should be related to pharmacokinetics of exposure to the cytostatic agent 
and its active metabolites.(11;22) However, research on post infusion cooling time is 
very scarce. In daily practice, post-infusion cooling times range from 15 minutes to 4 
hours.(12;17-23;25-28;30;32;34-37) A study comparing the effect of a shorter post-
infusion time in patients treated with docetaxel (90 versus 45 minutes) showed no 
difference in results on hair preservation (95% versus 79% did not need head 
covering).(39) Therefore, a new docetaxel study has started in which patients are 
randomized between 45 versus 20 minutes of post-infusion cooling time. In contrast, in 
breast cancer patients treated with adjuvant FEC chemotherapy for which scalp cooling is 
less effective (about 50% no head covering), it is investigated whether prolonging the 
post-infusion cooling time to 150 minutes is favorable over 90 minutes.  
 
Scalp cooling techniques 
Several techniques have been used to induce hypothermia: chilled air, bags with crushed 
ice, frozen cryogel packs or packs with an endothermic cooling reaction, special caps with 
cryogel and an insulation layer, and caps connected to a cooling device using air or fluid 
as a medium and equipped with a thermostat.(2;12;18;20;26;30;32-37;40;41)  Few 
studies compared the effectiveness of different methods of scalp cooling.(30;32;34) 
Dean et al compared a Kold Kap® device with ice packs in the treatment of 62 patients 
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with doxorubicin.(34) Sixty-three percent of Kold Kap® patients and 56% of ice pack 
patients did not require wigs. Although cooling devices using air or fluid as a medium and 
equipped with a thermostat (figure 2) provide more constant cooling that can be 
maintained for longer, there is no conclusive evidence that permanently cooled caps give 
better hair preservation. Studies comparing skin temperatures and skin perfusion as 
obtained with various methods of scalp cooling are lacking. Although bags with ice as 
well as special caps are both well tolerated, caps are lighter in weight and easier to 
apply, which might offer a comfort advantage. 
 
Figure 2. Cooling device equipped with a thermostat 
 
 
Side effects and contraindications of scalp cooling 
Scalp cooling is generally well tolerated.(2;3;11;42) Results obtained from patients 
appear to indicate high levels of comfort and acceptability with evidence of only minor 
and reversible side-effects.(1) The most often reported side-effects of scalp cooling are: 
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headaches, complaints of coldness and/or uncomfortable sensations and among others 
claustrophobia.(11;20;42) Scalp cooling is contra-indicated in cases of cold sensitivity, 
cold agglutin disease, cryoglobulinemia, cryofibrinogenemia and post-traumatic cold 
dystrophy.(11) Scalp metastases have rarely been reported in the literature but caution 
regarding its development has been a limitation for the broad-scale application of scalp 
cooling during chemotherapy.(6;43) Theoretically, tumour cells that have seeded in the 
scalp might not receive adequate chemotherapy during hypothermia allowing them to 
grow at a later date.(6) Since various studies have reported  recently on the safety of 
scalp cooling (44;45), a feasibility studies on scalp cooling in oncology patients have 
recently started in the United states. 
 
DISCUSSION  
While the incidence and severity of alopecia as a side effect of chemotherapy depends on 
the type and dose of chemotherapy(6;9;11-13), the outcome of hair preservation by 
scalp cooling is often unpredictable and varies between patients. The effectiveness of 
scalp cooling to prevent CIA depends on various factors such as patient characteristics, 
chemotherapy characteristics and scalp cooling characteristics. Unfortunately, there are 
hardly any randomized studies on the effectiveness and safety of scalp cooling in CIA. 
Only few studies have investigated which patient characteristics could be of influence and 
which method of scalp cooling is the most effective. In this review we found that scalp 
cooling results are better with certain chemotherapy types (taxanes). Results are less 
favourable at higher doses of chemotherapy. Skin temperature seems to play an 
important role, but until now, there is no evidence for a cut-off point under which 
alopecia can be prevented by scalp cooling. There are suggestions in the literature that a 
subcutaneous scalp temperature below 22°C is required for hair preservation, but as 
these studies on temperature used different and obsolete scalp cooling techniques, there 
is no conclusive evidence so far. Ideally scalp cooling should be applied more patient 
tailored. If a threshold level of scalp temperature is to be a critical issue, timing and 
technique of scalp cooling should be adapted to individual measurements of skin 
temperature. To advise patients on an individual basis on scalp cooling in preventing CIA, 
factors like optimal temperature and post-infusion cooling time should be investigated 
further. At present, various hospitals in Europe, Canada and Japan are already using 
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Results of scalp cooling during anthracycline containing chemotherapy depend  
on scalp skin temperature 
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Objectives: The success of scalp cooling in preventing or reducing chemotherapy 
induced alopecia (CIA) is highly variable between patients undergoing similar 
chemotherapy regimens. A decrease of the scalp skin temperature seems to be an 
important factor, but data on the optimum temperature reached by scalp cooling to 
prevent CIA are lacking. This study investigated the relation between scalp skin 
temperature and its efficacy to prevent CIA. 
Materials and methods: In this explorative study, scalp skin temperature was 
measured during scalp cooling in 62 breast cancer patients undergoing up to six cycles of 
anthracycline containing chemotherapy. Scalp skin temperature was measured by using 
two thermocouples at both temporal sides of the head. The primary end-point was the 
need for a wig or other head covering. 
Results: Maximal cooling was reached after 45 minutes and was continued for 90 
minutes after chemotherapy infusion. The scalp skin temperature after 45 minutes 
cooling varied from 10°C to 31°C, resulting in a mean scalp skin temperature of 19ºC 
(SEM: 0,4). Intrapersonal scalp skin temperatures during cooling were consistent for 
each chemotherapy cycle (ANOVA: p=0,855). Thirteen out of 62 patients (21%) did not 
require a wig or other head covering. They appeared to have a significantly lower mean 
scalp skin temperature (18ºC; SEM: 0,7) compared to patients with alopecia (20ºC; 
SEM: 0,5) (P=0,01). 
Conclusion: The efficacy of scalp cooling during chemotherapy is temperature 
dependent. A precise cut-off point could not be detected, but the best results seem to be 
obtained when the scalp temperature decreases below 18ºC.   
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INTRODUCTION  
Alopecia is a much feared side effect of chemotherapy and may have an impact on 
treatment decisions(1-6). Scalp cooling still remains the only current intervention to 
prevent chemotherapy induced alopecia (CIA). It is assumed that scalp cooling works by 
inducing local vasoconstriction and reduction of metabolism of the administered 
cytostatic agents(7,8). Vasoconstriction reduces the blood flow to the hair follicles in the 
period of peak plasma concentration of the relevant chemotherapeutic agent. Reduced 
metabolic activity makes hair follicles less vulnerable to the damage caused by 
chemotherapy. Although a decrease of the scalp skin temperature seems to be relevant 
for the results of cooling, data on the optimal temperature required for hair protection 
are scarce. There are suggestions in the literature that a subcutaneous scalp skin 
temperature below 22 degree Celsius (ºC)(9) (corresponding to an epicutaneous scalp 
temperature below 19ºC(7)) is required for hair preservation, but considerable variations 
have been reported on the desirable scalp temperature reached during scalp 
cooling.(7,9-13) Hillen et al.(11) attributed the success of their air-cooling method in 
part to achieving epicutaneous temperatures below 15ºC, whereas the average 
epicutaneous scalp temperature of three volunteers recorded in a study of Massey(13) 
was 16ºC. Al-Tameemi et al.(14) used in vitro models to provide evidence that 
temperature conditions may be critical in the efficacy of cooling by rescuing cells from 
drug mediated toxicity. Although previous in vitro reports concluded that further cooling 
below 22ºC would not provide any further protection against doxorubicin-mediated 
keratinocyte cytotoxicity(15), it was shown that lowering the temperature from 22ºC to 
18º and even further to 14ºC in human keratinocyte models resulted in a better degree 
of rescue from drug cytotoxicity. Based on the current available knowledge, it is not 
possible to draw conclusions on the optimal scalp temperature for effective cooling. 
To investigate the relation between the obtained scalp skin temperature during 
scalp cooling and its outcome in preventing CIA, we measured scalp skin temperatures 
during the procedure of scalp cooling in breast cancer patients treated with anthracycline 
containing chemotherapy.  
 
MATERIALS AND METHODS 
We conducted an explorative single-centre study between August 2010 and January 2014 
at the department of Internal Medicine of the Medical Centre Alkmaar, the Netherlands. 
The study enrolled patients with primary breast cancer who were planned for adjuvant 
chemotherapy with up to six cycles of 5-Fluorouracil-Epirubicin-Cyclophosphamide (FEC) 
or Adriamycin-Cyclophosphamide (AC) and who were willing to use scalp cooling to 
prevent CIA. The study was approved by an independent ethics committee and institution 
review board. All procedures were conducted in accordance with the 1964 Helsinki 
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Declaration and its subsequent amendments. Written informed consent was obtained 
from all patients included in the study.  
Inclusion criteria were primary invasive breast cancer without distant metastases. 
Patients had to be planned for treatment with three to six cycles FEC combination 
chemotherapy with an epirubicine dose of 90-100 mg/m2 at 3-weekly intervals or with 
AC combination chemotherapy with doxorubicin at a dose of 60 mg/m2. Subsequent 
chemotherapy cycles consisting of docetaxel monotherapy (100 mg/m2) were allowed 
after 3 FEC cycles. Patients were excluded if they lacked basic proficiency in Dutch, if 
they were unable to understand the patient information brochure or if they suffered from 
cold sensitivity, cold agglutinin disease, cryoglobulinaemia, cryofibrinogenaemia or cold 
posttraumatic dystrophy.  
The one-person Paxman cooling machine (PSC-1) was used in this study. The 
temperature of the coolant in the refrigeration tank was -10°C. This temperature is a 
standard set-up installed by the manufacturer. The cool cap was applied before cooling, 
with a pre-infusion cooling time of 45 minutes before the start of intravenous infusion of 
chemotherapy. Scalp cooling was continued during the administration of the 
chemotherapy with a post-infusion cooling time of 90 minutes after the end of 
chemotherapy infusion. Scalp cooling was applied in all planned cycles of chemotherapy, 
unless the patient decided to stop the cooling procedure because of hair loss, side effects 
or for patients’ preference.  
At baseline, patient characteristics and objective hair quantity were collected. Objective 
hair quantity was measured with a Hair Check. The mechanical device compresses a 
bundle of hair in a disposable cartridge from a delineated area of the scalp and measures 
its cross-sectional area (Hair Mass Index, HMI). HMI incorporates both density and 
diameter and was measured at both temporal sides. Tolerance of scalp cooling was 
measured during all visits by a Visual Analogue Scale (VAS) of 0-10, in which 0 
represented ‘not tolerable at all’ and 10 meant ‘very tolerable’. Patients were also asked 
whether they experienced other side effects such as headaches. The success of scalp 
cooling was defined in terms of the patient’s self-determined need to wear a wig or other 
head covering. Patients were considered evaluable for hair preservation if they were 
treated with at least three cycles of chemotherapy or if they discontinued scalp cooling 
due to severe hair loss. The epidermal temperature at the surface of the scalp was 
measured using two calibrated J type thermocouples that were fixed with medical glue at 
the left and right temporal side. To ensure that the registered temperature was a good 
measure for the skin temperature, each thermocouple end was modified with a specially 
developed aluminium disc with a diameter of 4 mm and a thickness of 0.5 mm. This 
facilitated the attachment to the scalp skin and, in combination with the medical glue, 
ensured that the thermal resistance between the thermocouple and the scalp skin was 
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lower than the thermal resistance between the thermocouple and the cold cap. The 




Data were collected using standard forms, which were compiled into a SPSS database 
(SPSS version 20.0).  
A paired t-test was used to check differences between the two measuring positions on 
the left and right temporal side. Differences in temperature between patients with and 
without head covering were analysed by the Mann-Whitney test. Repeated analysis of 
variance (ANOVA) was used for intergroup differences. All tests of significance were two-
sided, and differences were considered statistically significant when p<0,05. All tests 




In this study a total of 62 female patients with breast cancer were included. Patient 
characteristics and the efficacy of scalp cooling are listed in Table 1. The median age of 
the patients was 60 years. The mean baseline HMI was 64 (range 24-101). 
All patients were treated conform the protocol, with a median of 3 cycles of 
chemotherapy and scalp cooling. The median duration of scalp cooling was 195 minutes 
per cycle. All patients were evaluable for hair preservation and side effects. Four patients 
were not evaluable for temperature measurements because of probe dislocation or 
because probes came loose. At the time of data cut-off (January 1, 2014), the median 















Table 1. Patient characteristics  





Patients included 62  13 (21%) 49 (79%) 
Median age, years (range) 60 (32-74)   
Epirubicin 50 (81%) 8 (16%) 42 (84%) 
  6x F500/E100/C500 28 (45%) 5 (18%) 23 (82%) 
  3x F500/E100/C500 followed by     
  3xT100 
    Overall 3xFEC, 3xT 
    Result after 3xFEC 








Adriamycin 12 (19%) 5 (42%) 7 (58%) 
  4x A60/C600 10 (16%) 4 (40%) 6 (60%) 
  6x A60/C600dd 2    (3%) 1 (50%) 1 (50%) 
Mean HMI (range) 64 (24-101)   
Median number of cycles with scalp 
cooling (range) 
3 (1-6)   
F: 5-fluorouracil; E: Epirubicine; C: Cyclofosfamide; A: Adriamycine; T: Docetaxel 
dd: every two weeks 
 
Scalp temperature 
Temperature measurements at the left and right temporal side of the head did not show 
significant differences. Scalp skin temperatures were therefore reported as the mean of 
the two measuring points. Maximal cooling was reached after 45 minutes and was 
continued for 90 minutes after chemotherapy infusion. The scalp skin temperature 
following 45 minutes cooling varied between patients from 10°C to 31°C, resulting in a 
mean scalp skin temperature of 19ºC (SEM: 0,4). However, in each individual patient, a 
consistent temperature was obtained on repeated measurement (ANOVA: P=0,855) 
(figure 1).  
 
Figure 1. Mean scalp skin temperatures in degrees Celcius on repeated measurement in all patients during 
scalp cooling during 6 cycles of anthracycline-containing chemotherapy 
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Prevention of hair loss 
The most pronounced hair loss was recorded after cycle 1: 40% of the patients lost their 
hair after the first treatment. Thirteen out of 62 patients (21%) showed satisfactory hair 
retention during anthracycline containing chemotherapy (Table 1). Although these 
patients suffered from slight hair loss, they did not feel the need to wear a wig or other 
head covering. The pattern of hair loss (global or patchy) was measured after every cycle 
of chemotherapy. 85% of the patients with global and 75% of the patients with patchy 
hair loss required a head covering. The baseline HMI score was not predictive for hair 
loss (HMI no head covering 61; HMI head covering 64; p=0.7) Figure 2 and table 2 show 
the mean scalp skin temperatures during scalp cooling for patients with and without head 
covering. Patients with good hair retention had a mean scalp skin temperature of 18ºC 
(SEM: 0,7) while patients with hair loss resulting in the use of a wig or other head 
covering had a mean scalp skin temperature of 20ºC (SEM: 0,5) (P= 0,01) (Table 3). 
Because of the high variation in mean scalp skin temperatures in our patients, it was not 
possible to detect a threshold scalp skin temperature below which hair retention was 
always observed.  
 
 




Table 2. Mean scalp skin temperatures in degrees Celsius during scalp cooling in all patients 
Time (minutes) No head covering 
mean        SEM 
Head covering 
mean       SEM 
P-value 
T=0  
(start scalp cooling) 
33 0,2 34 0,1 0,46 
T=10 23 0,7 24 0,4 0,02 
T=20 19 0,6 21 0,4 0,01 
T=30 18 0,6 20 0,5 0,004 
T=45  
(start chemotherapy) 
18 0,7 20 0,5 0,01 
T=75 17 0,7 20 0,5 0,02 
T=105  
(stop chemotherapy) 
17 0,7 19 0,5 0,001 
T=135 17 0,7 19 0,5 0,01 
T=165 17 0,6 19 0,5 0,004 
T=195  
(stop scalp cooling 
17 0,6 19 0,5 0,01 
 
Table 3. Mean scalp skin temperatures in degrees Celsius after 45 minutes pre-infusion cooling according to 
the number of chemotherapy cycles 
 No head covering 
mean        SEM 
Head covering 
mean         SEM  
P-value 
Cycle 1 (N= 52) 17 1,1 19 0,6 0,10 
Cycle 2 (N= 29)  18 1,9 21 1,2 0,15 
Cycle 3 (N= 22) 17 1,1 20 1,2 0,11 
Cycle 4 (N= 9) 18 1,8 21 2,5 0,56 
Cycle 5 (N= 7) 18 3,7 19 3,2 0,86 
Cycle 6 (N= 7) 20 1,0 20 2,6 1,00 
Mean cycle 1-6 18          0,7         20 0,5 0,01 
      
Toxicity and tolerance 
Scalp cooling was very well tolerated. A VAS score for tolerance of scalp cooling was 
performed after 192 cooling procedures, resulting in a mean score of 8 (SD: 1,9). Only 
one patient stopped scalp cooling because of intolerance after cycle 4. Information about 
headaches was reported after 194 cooling procedures: in 163 sessions (84%) patients 
reported no headache; while headache was reported as minimal, moderate or severe in 
23 (12%), 4 (2%) and 4 (2%) sessions, respectively. Only fourteen percent of all 
patients in the study used paracetamol somewhere during their cycles to prevent 
headaches. No other side effects were reported. (Table 4). No scalp metastases were 
reported during follow up. 
 
Table 4. Tolerance and side effects of scalp cooling 
 N   (%) 
Tolerance (VAS 0-10a) ± SD 8 (±1,9) 
Reasons to stop scalp cooling other than hair loss 
  Intolerance 
  Chemotherapy finished or interrupted 
  Other 
 
1    (2) 
23 (37) 
4    (6) 
a0 represents ‘not tolerable’ and 10 means ‘very well tolerable’ 
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DISCUSSION 
To our knowledge this is the first study measuring scalp skin temperature during scalp 
cooling with a Paxman scalp cooling machine to prevent CIA in patients treated with 
anthracycline containing chemotherapy. Maximal cooling was reached after 45 minutes 
and was continued for 90 minutes after chemotherapy infusion. Intrapersonal scalp skin 
temperatures during cooling were consistent for each chemotherapy cycle, but scalp skin 
temperatures were highly variable between patients, ranging from 10°C to 31°C, 
resulting in a mean scalp skin temperature of 19ºC. Thirteen out of 62 patients (21%) 
did not require a wig or other head covering and showed satisfactory hair preservation. 
These patients appeared to have a significantly lower mean scalp skin temperature 
(18ºC; SEM: 0,7) during cooling than patients with alopecia (20ºC; SEM: 0,5) (P=0,01). 
The exact determinants on the efficacy of scalp cooling in the prevention of CIA 
are unknown(16-18). Factors like the type and dose of chemotherapy can influence the 
outcome of scalp cooling(16). Based on the results of this study, we can conclude that 
the temperature of the scalp skin is another important variable related to the efficacy of 
scalp cooling to prevent hair loss. Patients with good hair retention reached significant 
lower scalp skin temperatures than patients with hair loss. These results are in line with 
the study of Gregory et al.(9) who investigated scalp cooling by frozen cryogel packs in 
24 patients treated with doxorubicin and vincristine. They observed a consistent 
temperature in each patient after repeated cooling with maximal cooling after 20 to 30 
minutes. Intradermal scalp skin temperature varied from 19 to 29 degrees Celsius with 
significantly lower temperatures in patients with good hair retention (21 versus 24°C, P < 
0,001). Other studies on scalp skin temperature were performed in healthy man, not 
treated with chemotherapy (Table 5). We could not detect a precise threshold 
temperature below which hair preservation was likely. However, the best results seem to 
be obtained when the scalp temperature decreases below 18ºC. In reports on scalp 
cooling, many authors refer to Gregory et al.(9) with 22°C subcutaneously (19ºC 
epicutaneously) as a threshold temperature which patients have to reach for effective 
cooling. This cut-off point is based on one study with a limited number of patients treated 
with chemotherapy regimens with lower dosages than used nowadays and outdated scalp 
cooling techniques. Our results confirm this cut-off point with modern scalp cooling 
techniques and adequately dosed chemotherapy regimens. 
There is currently no satisfactory explanation for the wide scalp temperature variation 
between patients. Some persons consistently respond to scalp cooling with only a minor 
reduction in subcutaneous temperature. This might be due to a greater insulative power 
of the hairs or dermis(7). It might also be due to enhanced dissipation of heat structures 
below the subcutaneous tissue, or due to thermal reflex differences with regard to skin 
perfusion(7). Janssen et al.(19) explain the variation by anatomical differences such as 
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head shape and thickness of the insulating fat layer. However, Gregory et al.(9) report 
that the large variation in scalp temperature between patients in their study could not be 
explained by differences in hair thickness or density of scalp tissue. Although large 
variations were found between patients in our study, the reached degree of cooling in 
individual patients was very consistent on repeated cycles of chemotherapy. Differences 
between patients were therefore not due to changes in the procedure.  
Initial hair mass as measured by the Hair Check was not predictive for the 
severity of hair loss during scalp cooling. Therefore, the efficacy of scalp cooling in 
preventing CIA is independent of having either thin or thick hair. 
 Accurate measurement of the scalp skin temperature during scalp cooling is 
difficult. Needle thermometers can be inserted into the scalp skin to investigate the 
intradermal temperature(7,9-11,20). These measurements record the exact temperature 
without bias from the temperature of the cooling cap, but results of different studies are 
difficult to compare and these intradermal measurements are a burden for patients. 
Surface temperatures are patient friendly and can be recorded by using thermocouples 
attached to the skin(7,10-13,20,21). These measurements are easier to compare, but a 
major disadvantage is the probable influence of the cooling cap. However, Bulow et al.(7) 
demonstrated a close relationship between the epicutaneous and the subcutaneous 
temperatures during cooling, indicating that the influence of the cooling cap can be 
neglected.  
The position of the temperature probes on the scalp is poorly described in most 
studies. Researchers do not indicate in which region of the scalp the probes were placed. 
When described, the frontal and parietal region are mostly used to measure scalp skin 
temperature(7,10,13,21). The top of the head is found to be less responsive to 
cooling(10,13,17). Massey(13) observed that the temperature at the top of the head was 
1°C higher than at other places of the scalp. This region is most extensively affected by 
alopecia as we also observed at images that were taken at different time points in the 
study (Figure 3). Despite this, there seemed no difference in the need for a head 
covering between patients with global or patchy hair loss. The probes in our study were 
placed on the left and right side of the head, which was found to be a temperature-stable 
region according to Ekwall et al.(10). A third measurement would have been an 
interesting addition to find out whether the temperature variability between the temporal 
area and the crown might have been a predicting factor for the requirement of a head 
covering. Unfortunately, for practical reasons, only the temporal scalp skin temperatures 
were measured. This is simultaneously a limitation of our study as relation to the crown 
temperature remains unknown as well as it’s prediction for requirement of head covering. 
Scalp cooling was very well tolerated (VAS= 8). Nevertheless 15 patients (24%) 
reported a (mostly mild) headache somewhere during at least one of their cycles. 
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However, only one patient stopped scalp cooling because of intolerance, which is 
comparable with the literature(8,13,22). The use of paracetamol as premedication is no 
standard care in the chemotherapy regimens used in this study. Only fourteen percent of 
all patients in the study used paracetamol somewhere during their cycles to prevent 
headaches. This rejects the argument of doctors and nurses who do not to offer scalp 
cooling because it would be too hard to tolerate(23). 
 
   
 Baseline           After 4 cycles FEC 
 
Figure 3: The top of the head is most extensively affected by alopecia 
 
Table 5: Results of studies on skin temperature during scalp cooling 
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aOnly Gregory et al. included patients in their study and draws conclusions about temperature in relation to the 




When using scalp cooling to prevent anthracycline-induced alopecia, patients with 
satisfactory hair preservation appeared to have a significantly lower mean scalp skin 
temperature (18ºC; SEM: 0,7) during cooling than patients with alopecia (20ºC; SEM: 
0,5) (P=0,01). To obtain optimal results of scalp cooling to prevent chemotherapy 
induced alopecia, a scalp skin temperature of at least 18°C should be reached. Apart 
from the type or dose of chemotherapy, the obtained scalp skin temperature during scalp 
cooling is a very important factor to prevent hair loss. Improvements in scalp cooling 
machines should focus on possibilities to measure scalp skin temperature and the 
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ABSTRACT 
Purpose: For patients, chemotherapy-induced alopecia (CIA) is one of the most 
distressing side-effects of treatment. Scalp cooling can prevent or minimise CIA; the 
results may depend on the duration of cooling. Since a previous study on post-infusion 
cooling time in patients treated with docetaxel chemotherapy found no difference 
between 90 and 45 minutes, we investigated whether hair-preserving results could be 
maintained with a shorter post-infusion cooling time. 
Methods: In this prospective multi-centre randomised study, 134 patients who started 
treatment with docetaxel 75-100 mg/m2 in a 3-weekly schedule were randomly assigned 
in a 1:1 ratio to a post-infusion cooling time of 45 minutes or 20 minutes. The primary 
end-point was the need for a wig or other head covering as assessed by the patient. A 
visual analogue scale (VAS) with a range from 0 (not tolerable) to 10 (very tolerable) 
was used to measure tolerance. 
Results: Scalp-cooling results were similar for 45 minute and 20 minute post-infusion 
cooling times. Thirty-three out of 45 patients (73%) treated with 20 minutes of post-
infusion cooling did not need a form of head covering, compared with 41 out of 52 
patients (79%) treated with 45 minutes of post-infusion cooling (p=0.5). The procedure 
was well tolerated (mean Visual Analogue Score 8,3). Six patients stopped due to 
intolerance during the first treatment cycle. 
Conclusions: A 20 minute post-infusion cooling time is effective and tolerable for 
patients treated with scalp cooling to prevent docetaxel-induced alopecia.  
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INTRODUCTION 
For patients chemotherapy-induced alopecia (CIA) is one of the most distressing side-
effects of treatment. It has psycho-social implications and may affect body image and 
acceptance of treatment.[1-4] In the past two decades, a considerable amount of 
intensive research has been conducted into other chemotherapy related side-effects, 
such as nausea and fatigue. The treatment of these symptoms has since improved. CIA 
remains an issue that is difficult to resolve. For some patients CIA is a reason to refuse 
certain types of chemotherapy.[5;6] Despite the importance of hair loss for patients, 
alopecia is infrequently mentioned in phase II and III oncology trials. Although CIA is not 
life threatening and rarely leads to rejection of chemotherapy, it should be incorporated 
as an important patient-reported outcome measure in pharmaceutical trials. When there 
are no survival benefits between cytotoxic treatments, quality-of-life issues such as CIA 
might be decisive.[7]  
Scalp cooling is used to prevent CIA (figure 1).[8] It is assumed that it reduces 
skin temperature, thereby affecting the exposure and metabolism of cytotoxic agents in 
the hair follicles.[9;10] The hair-preserving effects of scalp cooling are variable, mainly 
depending on type and dose of chemotherapy and probably on degree and duration of 
cooling.[10-12] In theory, the scalp should remain cooled until the level of active drug or 
its metabolites is reduced to sufficiently low levels in the plasma.  
 




Docetaxel is a semi-synthetic taxoid and is effective against various 
cancers.[13;14] It is usually administered as a 1-h intravenous infusion repeated every 
21 days, at a recommended dose of 75 mg/m2 or 100 mg/m2 depending on tumour type 
and use as a single or combined agent. Docetaxel-induced alopecia is common at doses 
higher than 55 mg/m2 and has been observed in over 80% of patients at doses higher 
than 70 mg/m2.[13-17] The pharmacokinetics of docetaxel fit a tri-exponential curve: the 
α, β and γ half-lives with a 115 mg/m2 1-h infusion are 4 min, 36 min and 22 h, 
respectively.[14] As data regarding the concentration and duration of exposure of 
docetaxel that causes alopecia are lacking, the optimum scalp cooling time remains 
unclear. In addition, there is considerable intra-individual variation in half-life times 
among patients who are treated with docetaxel.[14] Consequently, recommendations for 
scalp-cooling times are often based upon past experience or are arbitrary.[18;19] In 
daily practice, post-infusion cooling times range from 15 minutes to 4 hours.[11] Scalp 
cooling has a hair-preserving result in 61-94% of docetaxel-treated patients with a post-
infusion cooling time of 15-90 minutes and depends on dose and treatment 
schedule.[12;19-22]  
The duration of post-infusion cooling implies a prolonged stay on the 
chemotherapy ward; this is potentially a disadvantage both for patients and for the 
logistics of the clinic. As a previous study on post-infusion cooling time in patients treated 
with docetaxel chemotherapy found no difference between 90 and 45 minutes, we 
investigated whether hair-preserving results could be maintained with an even shorter 
post-infusion time of 20 minutes.[22] 
 
PATIENTS AND METHODS 
Patients were enrolled in this prospective multi-centre randomised study between 
October 2009 and May 2013. The study was approved by an independent ethics 
committee and institution review board. All procedures were conducted in accordance 
with the 1964 Helsinki Declaration and its subsequent amendments. Specialised oncology 
nurses informed patients about the study. Written informed consent was obtained from 
all individual participants included in the study. Inclusion criteria were that patients were 
undergoing docetaxel-containing schedules at 3-weekly intervals and were aged 18 or 
over. Exclusion criteria were treatment with docetaxel in sequential schemes (docetaxel 
monotherapy after 5-fluouracil, epirubicin, cyclophosphamide (FEC) or after adriamycin, 
cyclophosphamide (AC)), treatment with docetaxel combined with adriamycin and 
cyclophosphamide (TAC), alopecia before the start of the study, haematological 
malignancies and rare disorders like cold sensitivity, cold agglutinin disease, 
cryoglobulinaemia, cryofibrinogenaemia and cold posttraumatic dystrophy. Eligible 
patients who chose scalp cooling were randomly assigned to a post-infusion cooling time 
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of 45 minutes or 20 minutes in a 1:1 ratio. The random sequence was kept by an 
external centre (Comprehensive Cancer Organisation Netherlands, IKNL, location 
Eindhoven). 
All sixteen participating hospitals used the Paxman one-person cooling machine 
(PSC-1). The cap was applied according to the instructions for use in the nursing 
protocol. The temperature of the coolant in the refrigeration tank was -10°C. This 
temperature is a standard set-up installed by the manufacturer. The pre-cooling time was 
30 minutes before the start of the chemotherapy infusion. The cool cap remained on the 
scalp during the infusion period, 60 minutes being the standard. Scalp cooling was 
applied during all planned cycles of chemotherapy, unless the patient decided to stop the 
cooling procedure based on hair loss, side-effects or for other reasons.  
The success of scalp cooling was defined in terms of the patient’s self-determined 
need to wear a wig or other head covering (e.g. hat or scarf) to mask visible hair loss 
after docetaxel treatment. Patients additionally evaluated hair loss on the 4-point scale 
for alopecia (0=no change, 1=minimal hair loss, 2=moderate, 3=patchy alopecia, 
4=complete alopecia) of the World Health Organisation (WHO, offset Publication No. 
48).[23] Patients were considered eligible for evaluation of hair preservation if they were 
treated with at least two cycles of docetaxel chemotherapy or if they discontinued scalp 
cooling after one cycle due to severe hair loss. Tolerance of scalp cooling was measured 
by a (self-adapted) Visual Analogue Scale (VAS) of 0-10, in which 0 represented ‘not 
tolerable at all’ and 10 meant ‘very tolerable’. Patients were also asked whether they 
experienced other side-effects such as headaches.  
 
Statistical analysis 
The primary end-point was the need to wear a wig or other head covering as assessed by 
the patient. Nominal variables like hair loss, gender, chemotherapy, etc. were analysed 
using a Chi-square test. Ordinal variables, like the 10-point VAS-scale, WHO and pre- 
and post-infusion cooling times were analysed using the Mann-Whitney test. Age and 
follow-up were analysed using a t-test. The analyses were carried out on all randomised 
patients on an intention to treat (ITT) basis while a secondary analysis was performed on 
the subgroup of patients receiving at least 2 cycles of chemotherapy and scalp cooling. 
The power of the test was estimated as 80% with a two-sided α value of 0.05, which 
indicated a sample size of 40 evaluable subjects in each arm. Based on the number of 
patients who were not completely evaluable in an earlier multi-centre scalp cooling 
trial[22], we considered a sample size of 60 patients per arm. Finally 97 out of 134 
included patients were evaluable for hair preservation. Data were collected using 
standard forms, which were compiled into a SPSS database. All tests of significance were 
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two-sided, and differences were considered statistically significant when P<0.05. All tests 
were performed using SPSS software (version 20.0) for Windows XP. 
 
RESULTS 
In this study a total of 134 patients treated with docetaxel chemotherapy were entered 
and randomised to a post-infusion cooling time of 45 minutes or 20 minutes. The study 
was ended when the pre-determined number of enrolled subjects was obtained. Patient 
characteristics are listed in Table 1. The median age of patients was 64 years. There 
were no significant differences between the 45 and 20 minute group with respect to 
clinical characteristics and treatment. Most patients were treated for prostate cancer 
(43%) and received docetaxel monotherapy (84%). All patients were treated in 
accordance with the assigned randomisation. The median pre-infusion cooling time was 
33 minutes (IQR 15).  
 
Table 1. Patient characteristics 
 
 
20 minutes post 
infusion cooling 
time (n=64) 




Mean age, years (range)   64 (43-82)   64 (25-83) 1.0 
Gender   0.3 
  Male 36 (56%) 46 (66%)  
  Female 28 (44%) 24 (34%)  
Cancer   0.6 
  Breast 17 (27%) 20 (28%)  
  Lung 13 (20%) 9 (13%)  
  Prostate 26 (41%) 32 (46%)  
  Gastro-intestinal 1 (1%) 1 (1%)  
  Other 2 (3%) 2 (3%)  
  Missing 5 (8%) 6 (9%)  
Chemotherapy    0.7 
  Docetaxel monotherapy 55 (86%) 58 (83%)  
  Docetaxel combination therapy* 6 (9%) 8 (11%)  
  Missing 3 (5%) 4 (6%)  
Setting    0.8 
  Curative 5 (9%) 6 (10%)  
  Palliative 53 (91%) 54 (90%)  
Median number of cycles with scalp 
cooling 
5 5   
* Docetacel combined with doxorubicin, cyclophosphamide, gemcitabin, carboplatin or capecitabine 
** Chi-square results are invalid. because of cell counts less than 5 
 
 
At the time of data analysis (April 8, 2014), the median follow-up for patients in 
the 20 minute group was 6.5 months and 7.5 months for the 45 minute group (Table 2). 
Thirty-seven patients were not evaluable for hair preservation. Five patients stopped due 
to intolerance during the first chemotherapy cycle, 21 patients stopped chemotherapy 
before completing the second cycle, one patient died before hair loss could be reported, 
three patients decided to leave the study after randomisation, one patient was not 
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treated with docetaxel, one patient withdrew informed consent and five questionnaires 
could not be retrieved.  
 
Table 2. Tolerance, side-effects and follow up 











Tolerance (VAS 0-10*) ± SD   8.6 ±1.4   8.0 ±9.6 0.1 
Headache (any grade) 19 (31%) 19 (29%) 1.0 
Reasons to stop scalp cooling other than 
hair loss 
  ** 
  Intolerance 1 (2%) 5 (7%)  
  Chemotherapy finished or interrupted 46 (72%) 50 (71%)  
  Other 8 (13%) 10 (14%)  
Median follow up, months (IQR)  6.5 (6.3) 7.5 (6.9) 0.7 
*0 represents ‘not tolerable’ and 10 means ‘very well tolerable’ 
**Chi-square results are invalid because of cell counts less than 5 
  
In this study 97 patients were evaluable for hair preservation (Table 3). There was 
no significant difference in need to wear head covering in the 20 minute group compared 
to the 45 minute group (20 min, n=33/45 (73%) no head covering; 45 min, n=41/52 
(79%) no head covering; p=0.5). A significant difference in need to wear head covering 
was seen when the dosages of docetaxel were compared (75 mg/m2, n=5/65 (8%); 100 
mg/m2, n=14/25 (57%); p<0.0001) and gender (male, n= 59/62 (95%); female, n= 
15/35 (43%); p<0.0001) (Table 4).  
 
Table 3. Response to scalp cooling 









Evaluable for scalp cooling 45 52 0.5 
  Patients with head covering 12/45 (27%) 11/52 (21%)  
  Patients without head covering 33/45 (73%) 41/52 (79%)  
Not evaluable  19 (30%) 18 (26%)  
WHO* for alopecia    0.8 
  0                           22 (46%) 24 (45%)  
  1                           18 (37%) 18 (34%)  
  2                            7 (15%) 8 (15%)  
  3 1 (2%) 3 (6%)  











Table 4. Efficacy of scalp cooling depending on type and dosage of chemotherapy and gender 
 No head 
covering 
Head covering P value 
Chemotherapy    * 
  Docetaxel monotherapy 67 (78%) 19 (22%)  
  Docetaxel combination therapy 7 (70%) 3 (30%)  
     Docetaxel/ gemcitabin 1 0  
     Docetaxel/ carboplatin 5 2  
     Docetaxel/ capecitabin 1 0  
     Docetaxel/ cyclophosphamide 0 1  
Dosage    <0.0001  
  75 mg/m2 60 (92%) 5 (8%)  
  100 mg/m2 11 (44%) 14 (56%)  
Gender   <0.0001 
   Male  59 (95%) 3 (5%)  
   Female 15 (43%) 20 (57%)  
*Chi-square results are invalid because of cell counts less than 5 
 
During the follow-up period information on hair status was not available while 
scalp metastases were not reported. Scalp cooling was well tolerated. A VAS score for 
tolerance of scalp cooling was performed 471 times, resulting in a mean score of 8.3 
(Table 2). Information concerning headache was reported 488 times: in 417 (85%) 
sessions, patients reported no headache; in 55 sessions (11%) minimal; in 14 (3%) 
moderate; and in 2 (0.4%) sessions patients reported severe headaches. No other side-
effects were reported. 
 
DISCUSSION  
In the present study 74 out of 97 patients (76%) treated with scalp cooling did not need 
a head covering to cover visible hair loss after docetaxel chemotherapy, while no 
difference was found between 45 and 20 minute post-infusion cooling time. As 
mentioned, a previous study on scalp cooling to prevent docetaxel-induced alopecia 
found no difference between 90 and 45 minutes post infusion cooling times.[22] Of all 
the patients in that study, 84% (n=129) did not wear a head covering. Twenty minutes 
can therefore be advised as a standard post-infusion cooling time for patients treated 
with 3-weekly docetaxel-containing chemotherapy. This is a major benefit for both 
patients and hospitals, as patients can be discharged earlier and since the stay in hospital 
is shorter, more patients can be treated.  
 Hair preservation was very good, which is in accordance with the results of other 
scalp-cooling studies. Results were better at lower docetaxel dosages as also observed in 
other such studies.[12;19-22;24-26] However, because there was no significant 
difference between the 45 and 20 minute group with respect to dosage, conclusions on 
shortening post-infusion cooling times remain valid.  
Scalp cooling was very well tolerated (VAS= 8.3). Nevertheless 38 patients 
reported a (mostly mild) headache somewhere during at least one of their cycles. Five 
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patients (5.3%) stopped scalp cooling because of intolerance, which is comparable with 
findings in the literature.[10;18;22] This refutes the argument of some doctors and 
nurses who do not offer scalp cooling because it would be too hard to tolerate.[27] 
Comparing studies concerning hair preservation is complicated by the lack of a 
standardised methodology for evaluating hair loss.[28-30] To assess hair loss, the 
authors chose from among several widely accepted scales, such as the World Health 
Organisation (WHO) classification of chemotherapy-induced alopecia, the Common 
Terminology Criteria for Adverse Events (CTCAE) and Visual Analogue Scales (VAS). In 
the present study we asked patients whether a wig or head cover was used and we 
measured the degree of hair loss according to the WHO criteria. Recently, an objective 
method has become available to measure hair quantity: the cross-section trichometer 
[31], a very promising technology for research purposes.[32] However, the use of a wig 
or head cover as a parameter for patient satisfaction should remain the most important 
clinical criterion for the success of scalp cooling.[8] In future studies concerning scalp 
cooling and hair preservation, the use of a cross-section trichometer combined with 
previously used methods is strongly recommended. 
In this study 61% of patients were male. Contrary to prevailing assumptions, men 
also describe negative feelings about hair loss. Men’s experiences have been largely 
ignored and healthcare professionals should spend more time assisting men with 
adjustment to CIA.[33] Men are often treated with docetaxel, a regimen in which the 
results of scalp cooling proved to be very good (figure 2). In this study 95% of male 
patients did not need a head covering, against 43% of female patients. This is in 
agreement with previous findings.[19] However, the result in males may be 
overestimated, since men are in general less inclined to wear a wig or head covering. As 
upfront chemo-hormonal therapy for metastatic prostate cancer seems to improve 
overall survival, even more men will be treated with docetaxel in future.[34] It would be 
a major improvement if all men undergoing docetaxel chemotherapy were informed 
about the highly protective effect of scalp cooling in preventing CIA.  
Although the numbers are small, we can formulate a concrete recommendation on 
post-infusion cooling time for patients treated with docetaxel-containing schedules at 3-
weekly intervals. The pre-cooling time should remain at 30 minutes before the start of 
the chemotherapy infusion. The post-infusion cooling time can be adapted from 45 
minutes to 20 minutes.  
Another interesting aspect for investigation might be scalp cooling without a post-
infusion cooling time for cytotoxics with rapid clearance. Scalp cooling decreases the 
exposure of hair follicles to chemotherapy, but might also unnecessarily suppress the hair 
repair mechanism.[22;35]  
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Figure 2: Results of scalp cooling in a male patient who was treated with docetaxel 
   
             Cycle 1             Cycle 6 
 
The study was supported by Sanofi Aventis. Sanofi Aventis did not contribute to the 
study design, data collection, analyses and interpretation of data or to the writing of the 
report. The decision to submit the results for publication was made by the authors.  
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ABSTRACT 
Purpose: Scalp cooling as a method to reduce the incidence of chemotherapy induced 
alopecia (CIA) is increasingly used in daily practice worldwide. However, in patients 
treated with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC), scalp cooling fails in 
48-67% of patients. This study investigated the efficacy of extended duration of post-
infusion scalp cooling in breast cancer patients treated with this regimen. 
Methods: In this prospective multi-centre randomised study, 102 patients with early 
breast cancer treated with adjuvant FEC chemotherapy were randomly assigned in a 1:1 
ratio to a post-infusion cooling time of 90 or 150 minutes. The primary endpoint was the 
need to wear a wig or other head covering to mask visible hair loss. 
Results: Sixteen out of 48 patients (33%) treated with 90 minutes of post-infusion 
cooling did not need any head covering, compared with 21 out of 46 patients (45%) 
treated with 150 minutes of post-infusion cooling (p=0.2). WHO grade 2-3 (moderate-
complete) alopecia was reported more often in patients treated with 90 minutes post-
infusion cooling time (n= 25/51 (49%) versus n=17/51 (33%); p=0,02). Scalp cooling 
was well tolerated (mean Visual Analogue Score 7.4) and only three patients (3%) 
stopped due to intolerance during treatment.  
Conclusions: Extending the duration of 90 minutes post-infusion scalp cooling to 150 
minutes in patients treated with adjuvant FEC chemotherapy was well tolerated but did 
not significantly diminish the need for head covering. However, grade 2-3 alopecia was 
seen less often with prolonged post-infusion scalp cooling. 
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INTRODUCTION 
As there is a growing awareness for optimal supportive care in patients with cancer, 
research increasingly focusses on minimizing side effects of chemotherapy to improve 
quality of life. [1] The social and psychological consequences of chemotherapy induced 
alopecia (CIA) are obvious to everyone and may affect body image and acceptance of 
treatment. [1-4] Scalp cooling as a method to reduce the incidence of CIA is increasingly 
being used in daily practice worldwide. [5-7] The mechanism of scalp cooling during 
treatment with chemotherapy is based on the theory that reducing the scalp skin 
temperature during the administration of chemotherapy affects the exposure to and 
metabolism of cytotoxic agents in the hair follicles. [8, 9] The hair-preserving effects of 
scalp cooling are highly variable, mainly depending on type and dose of chemotherapy 
and probably also on the temperature and duration of cooling. [9-12] Scalp cooling has 
only limited beneficial effect in patients who are treated with anthracyclines.[13] 
Epirubicin, a frequently used anthracycline, is a semisynthetic derivate of 
doxorubicin and has a wide range of antitumor activity. [14, 15] Being effective in the 
treatment of breast cancer it is frequently used as adjuvant therapy in patients with early 
breast cancer or palliative chemotherapy for metastatic disease. [15] The drug may be 
administered alone or in combination with other agents. In the adjuvant setting for 
breast cancer, a commonly used anthracycline-containing combination chemotherapy 
regimen is 5-fluorouracil together with epirubicin and cyclophosphamide (FEC). [14] 
Standard dose of the FEC regimen consists of fluorouracil 500-600 mg/m2, epirubicin 90-
100 mg/m2 and cyclophosphamide 500-600 mg/m2 administered intravenously once 
every 3 weeks. A very common side effect of this regimen is complete alopecia. [14] 
Theoretically, the duration of scalp cooling after the infusion of chemotherapy should be 
related to pharmacokinetics of exposure to the cytostatic agent and its active 
metabolites. [9, 11] The pharmacokinetics of epirubicin fit a tri-exponential curve with 
half-lives for the initial (α), intermediate (β) and terminal (γ) elimination phases of 
approximately 3 minutes, 1 hour and 30 hours respectively [14], but show considerable 
inter-individual variation. [15] Consequently, recommendations for post-infusion scalp-
cooling times are often based upon past experience or are arbitrary. [13, 16] Indeed, in 
daily practice post-infusion cooling times range from 15 minutes to 4 hours. [10] In the 
Netherlands a duration of 90 minutes post-infusion cooling time has been arbitrarily 
chosen as the standard post-infusion cooling time for any chemotherapy regimen. FEC 
chemotherapy is frequently used as adjuvant treatment in patients with breast cancer 
and scalp cooling is increasingly being used in this setting to prevent CIA. However, scalp 
cooling fails in 48-67% of patients treated with this chemotherapy regimen. [13] To 
investigate whether the efficacy of scalp cooling could be improved by a longer post-
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infusion time we compared a post-infusion cooling time of 150 minutes versus 90 




The study enrolled female patients with primary breast cancer, aged 18 or older. They 
were planned for a minimum of three cycles FEC chemotherapy with an epirubicin dose of 
90-100 mg/m2 at 3-weekly intervals and were willing to use scalp cooling to prevent CIA. 
Patients with alopecia before the start of the study were excluded from the study. Also 
excluded were patients with (concomitant) haematological malignancies or 
contraindications for scalp cooling such as cold sensitivity, cold agglutinin disease, 
cryoglobulinaemia, cryofibrinogenaemia or cold posttraumatic dystrophy. 
 
Study design 
We conducted a prospective multi-centre randomised study in seven hospitals in the 
Netherlands. The primary endpoint of this study was the need to wear a wig or other 
head covering to mask visible hair loss. The severity of hair loss was evaluated on the 4-
point scale for alopecia (0=no change, 1=minimal hair loss, 2=moderate, patchy 
alopecia, 3=complete alopecia) of the World Health Organisation. [17] Tolerance of scalp 
cooling was measured on a 1-10 Visual Analogue Scale (VAS), with 10 being the most 
tolerable. Other side-effects such as headaches were also recorded. Patients were 
considered eligible for final analyses if they were treated with at least two cycles of FEC 
chemotherapy or if they discontinued scalp cooling after one cycle due to severe hair 
loss. Patients were randomly assigned to a post-infusion cooling time of 90 minutes or 
150 minutes with the allocation ratio of 1:1 (Figure 1). The random sequence was carried 
out following a predefined randomization schedule by an external independent centre 
(Netherlands Comprehensive Cancer Network (IKNL)). Each institutional review board 
approved the study before participants were enrolled. All procedures were conducted in 
accordance with the 1964 Helsinki Declaration and its later amendments. Patients were 
informed about the study by specialised oncology nurses. All patients gave written 




Figure 1. Consort 2010 flow diagram 
 
Intervention 
The Paxman one-person cooling machine (PSC-1), with a standard temperature of -10°C 
was used in this study by all participating hospitals. Oncology nurses applied the cool cap 
according to the instructions for use in the nursing protocol. The pre-cooling time was 30 
minutes before the start of the chemotherapy infusion and the cool cap remained on the 
scalp during the infusion period of 60 minutes. Scalp cooling was applied during all 
planned cycles of chemotherapy, unless the patient decided to stop the cooling procedure 
because of hair loss, side-effects or for patients’ preference. 
 
Sample size and statistical analysis  
The sample size was calculated for the different cooling times. A power and sample size 
program was used to estimate the sample size (PS: Power and sample size calculation). 
[18] The primary endpoint was the need to wear a wig or other head covering to mask 
visible hair loss. Based on data from our registration study, the risk of hair loss for 
patients treated with the standard scalp cooling was approximately 50%. We assumed 
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that an improvement of at least 30% in the outcome of scalp cooling would be clinically 
relevant to justify the burden of a prolonged post infusion scalp cooling time of 150 
minutes. With a power set at 80%, 30% difference could be detected by 44 patients in 
each randomisation arm. Based on the expected drop-out after inclusion, 51 patients per 
arm were included. All outcomes were analysed with two-tailed tests at α=0.05, and 
differences were considered statistically significant when p<0.05. Analyses were 
performed using SPSS software (version 20.0) for Windows XP. Patient and treatment 
characteristics were analyzed using a Chi-square test. Response to scalp cooling and 
tolerance were analyzed using the Mann-Whitney test. Age and follow-up were analysed 
using a t-test. The analyses were carried out on all randomised patients on an intention-
to-treat (ITT) basis, while a secondary analysis was performed on the subgroup of 
patients receiving at least 2 cycles of chemotherapy and scalp cooling.  
 
RESULTS 
Patient and treatment characteristics 
Between March 2007 and July 2015 a total of 102 female patients were randomised to a 
post-infusion cooling time of 90 or 150 minutes. All patients were treated in accordance 
with the assigned randomisation of post-infusion duration of scalp cooling. Patient and 
treatment characteristics are listed in table 1. The mean age was 52 years. Thirty-six out 
of 102 patients (35%) were treated with 5 cycles FEC with an epirubicin dose of 90 
mg/m2, 35 patients with 6 cycles FEC with an epirubicin dose of 100 mg/m2, and 31 
patients with 3 cycles FEC (epirubicin dose 100 mg/m2) followed by 3 cycles docetaxel. 
There was no significant difference between patients in the 90 and 150 minutes group 
with respect to treatment characteristics. All patients were treated conform the study 
protocol with scalp cooling during FEC chemotherapy, for a median of 4 cycles. At the 
time of the data cut-off (December 7, 2015), the median follow-up of patients was 73 
months. 
 
Table 1. Patient and treatment characteristics  
 90 minutes post 
infusion cooling 
time (n=51) 




Mean age, years (range) 51 (30-72) 52 (40-69)  
Chemotherapy (type)    1.0 
  5x FEC 18 (35%) 18 (35%)  
  6x FEC 17 (33%) 18 (35%)  
  3x FEC followed by 3x TXT 16 (32%) 15 (30%)  
Chemotherapy (dose)    0.7 
  F(500a)E(90a)C(500a) 21 (41%) 19 (37%)  
  F(500a)E(100a)C(500a) 30 (59%) 32 (63%)  
Median number of cycles with scalp 
cooling ± SD 




In this study eight patients (7.8%) were not evaluable for hair loss. Two patients stopped 
scalp cooling due to intolerance before the second cycle was completed, one patient 
refrained from adjuvant FEC chemotherapy, one patient stopped chemotherapy before 
the second cycle was completed, one patient decided to leave the study after 
randomisation, two questionnaires could not be retrieved and in one patient the reason 
to stop was unknown.  
  Finally, a total of 94 out of 102 included patients was evaluable for hair 
preservation (Table 2). Thirty-seven out of 94 evaluable patients (40%) did not need to 
wear a wig or other head covering to mask hair loss during their therapy. There was no 
significant difference in the proportion of patients who wore a wig or head cover between 
the 90-minutes group and the 150-minutes group (n= 16/48 (33%) versus n= 21/46 
(45%); p=0.2). WHO-score for alopecia grade 2-3 (moderate-complete) was reported 
significantly more often in patients treated with 90 minutes post-infusion cooling time 
(n= 25/51 (49%) versus n=17/51 (33%); p=0,02). The planned number and type of 
adjuvant chemotherapy (5x FEC, 6x FEC or 3x FEC followed by 3x docetaxel) did not 
correlate with the need to wear head covering (p= 0.08). The need to wear head 
covering was 47% in patients treated with epirubicin at a dose of 90 mg/m2 compared to 
69% in patients treated with 100 mg/m2 (p=0.04) (Table 3). 
 
Table 2. Response to scalp cooling 
 90 minutes post 
infusion cooling 
time (n=51) 




Evaluable for scalp cooling efficacy 48 46  
Head covering   0.2 
  Patients with head covering 32 (67%) 25 (55%)  
  Patients without head covering 16 (33%) 21 (45%)  
Not evaluable  3   (6%) 5   (10%)  
WHOa for alopecia    0.02 
  0-1 10 (20%) 23 (45%)  
  2-3 25 (49%) 17 (33%)  
  missing 16 (31%) 11 (22%)  
a WHO, offset Publication No.48 [17] 
 
 
Table 3. Efficacy of scalp cooling depending on type and dosage of chemotherapy in 94 evaluable patients 







Chemotherapy (type)   0.08 
  5xFEC 18 (55%) 15 (45%)  
  6xFEC 10 (32%) 21 (68%)  
  3x FEC followed by 3x TXT 9 (30%) 21 (70%)  
Chemotherapy (dose)   0.04 
  90 mg/m2 19 (53%) 17 (47%)  
  100 mg/m2 18 (31%) 40 (69%)  
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Tolerance and safety analysis 
Scalp cooling was well tolerated, irrespective of the post-infusion duration (Table 4). 
Tolerance of scalp cooling, recorded by a VAS score was performed after 322 cooling 
procedures, and resulted in a mean score of 7,4 (SD: 2,1) There were 3 patients (3%) 
who stopped scalp cooling because of intolerance. Side effects such as headaches were 
recorded during 327 cooling procedures: in 238 sessions (73%) no headaches were 
reported; while headache was reported as mild, moderate or severe in 66 (20%), 20 
(6%) and 3 (1%) sessions, respectively. There were no scalp metastases reported during 
the follow up period. 
 
Table 4. Tolerance, side-effects and follow up 









Tolerance (VAS 0-10a) ± SD 7,5 ±2,0 7,3 ±2,2 0.8 
Reasons to stop scalp cooling other than 
hair loss 
  b 
  Intolerance 1       (2%) 2      (4%)  
  Chemotherapy finished or interrupted 25    (49%) 27  (53%)  
  Other 1       (2%)  5    (10%)  
Median follow up, months (range)  74 (15-106) 72 (8-108) 1.0 
a0 represents ‘not tolerable’ and 10 means ‘very well tolerable’ 
bChi-square results are invalid because of cell counts less than 5 
 
DISCUSSION 
In this randomized study performed in patients with early breast cancer treated with 
adjuvant chemotherapy with the FEC regimen, prolonging of the duration of 90 minutes 
post-infusion scalp cooling to 150 minutes was well tolerated but did not significantly 
diminish the need for head covering. However, grade 2-3 alopecia was observed less 
often with prolonged post-infusion scalp cooling. 
Thirty-seven out of 94 evaluable (40%) patients were successfully treated with 
scalp cooling to prevent CIA, corresponding with the results (33-52%) of FEC high dose 
chemotherapy in a large registry study on scalp cooling. [13]  
Our study has some limitations and may have been underpowered. At the start of the 
study, the standard chemotherapy regimen in the Netherlands for patients with primary 
breast cancer was 5 cycles FEC at an epirubicin dose of 90 mg/m2. Based on international 
guidelines, treatment with 6 cycles FEC at a dose of 100 mg/m2 was also given in some 
centers. However, there was no data available on the positive effect of scalp cooling at 
this higher dose. Therefore, the effect of scalp cooling in the FEC regimen at a dose of 90 
mg/m2, as was available from our registration data (50% efficacy), was used for power 
calculation. At present, after extension of our registry, the estimation of scalp cooling 
efficacy in the FEC regimen with epirubicin 90 mg/m2 proved to be correct (52% 
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efficacy). However, we found that the efficacy of scalp cooling in the FEC regimen with 
epirubicin 100mg/m2 is 33%.[13] Therefore, a significant difference in efficacy might 
have been missed.  
In our study, grade 2-3 alopecia was seen less often with prolonged post-infusion 
scalp cooling. Therefore, we cannot exclude a clinical meaningful difference between the 
two post-infusion cooling times. This should be explored further in studies with a larger 
sample size and quantitative methods to measure the degree of hair loss. However, even 
if the effect of 150 minutes post-infusion cooling would indeed be superior in a larger 
study, one should consider the long stay in the hospital which is less feasible for both 
patients and nurses and goes with increased costs for hospitals due to extended duration 
of nursing time and stay at the chemotherapy unit. 
The follow up in this study is very long (73 months, range 8-108 months), and 
can be explained by the long inclusion period of the study. Contrary to our expectations, 
it was difficult to motivate patients to be randomized between 90 and 150 minutes post 
infusion cooling time. This extended the period of inclusion in which the dose of FEC 
initially changed from 90 mg/m2 to 100 mg/m2 and later changed to a sequential 
schedule of three courses FEC with 100 mg/m2 epirubicin, followed by three courses 
docetaxel mono-therapy of 100 mg/m2. 
In recent years the Hair Check method has become available for objective hair 
loss measurement. [19] An objective and more sensitive method of measuring hair loss 
may especially be of value in the research on refining scalp cooling techniques to prevent 
CIA. However, patient reported outcome as a parameter for patient satisfaction remains 
the most important clinical criterion for the efficacy of scalp cooling. In order to compare 
scalp cooling outcomes, preferably a combination of a subjective clinical scale and an 
objective method like the Hair Check should be used, at least in clinical studies.  
 Several reports on the anthracycline pharmacokinetics point out the large 
inter-individual variations and the need for individualization of the doses based on 
measured plasma concentrations. [20, 21] Eksborg et al. measured that an increase in 
maximum plasma concentration of epirubicin was associated with an increasing degree of 
alopecia. [22] Therefore it might be interesting to investigate whether adapting the post-
infusion cooling time to the maximum plasma concentration could improve scalp cooling 
outcomes. 
The procedure of scalp cooling was very well tolerated (VAS=7.4) and 
independent of duration of post-scalp cooling. Nevertheless, 48 patients reported any 
grade headache (mostly mild) during at least one of their cycles. Only 3 patients stopped 
scalp cooling because of intolerance, both in line with the literature. [6, 9, 12, 16, 23, 
24]  
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In conclusion, our study did not significantly contribute to an overall favourable 
clinical effect of scalp cooling in reducing the use of head covering. However, it 
demonstrated that prolonging the post-infusion cooling time of the FEC (90-100mg) 
regimen did show some reduction of grade 2/3 alopecia after 150 minutes.  
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Purpose: Alopecia is one of the most distressing side effects of chemotherapy. 
Evaluating and comparing the efficacy of potential therapies to prevent chemotherapy-
induced alopecia (CIA) has been complicated by the lack of a standardized measurement 
for hair loss. In this study we investigated the correlation between patient-reported 
outcome assessments and quantitative measurement with the hair check to assess CIA in 
clinical practice.  
Method: Scalp cooling efficacy was evaluated by patients by World Health Organisation 
(WHO) of CIA, Visual Analogue Scale (VAS) and wig use. The Hair Check was used to 
determine the amount of hair (in mm2) per unit of scalp skin area (in cm2) (Hair Mass 
Index, HMI). CIA was also evaluated by doctors, nurses and hairdressers.  
Results: Baseline HMI was not predictive for hair loss. HMI declined throughout all 
chemotherapy cycles, which was not reflected by patient-reported measures. HMI 
correlated with patient-reported hair quantity before the start of the therapy, but not 
with WHO and/or VAS during therapy. Patient’s opinion correlated moderately with the 
opinion of doctors and nurses (ρ=0.50-0.56 respectively), but strongly with hair dressers 
(ρ=0.70). 
Conclusions: The Hair check is suitable to quantify the amount of hair loss and could 
complement research on refining outcome of scalp cooling, but the patient’s opinion 




Alopecia is one of the most distressing side effects of chemotherapy and may have an 
impact on treatment decisions. (Batchelor, 2001, Rosman, 2004, Hesketh et al., 2004, 
Mols et al., 2009) Scalp cooling is a treatment option to prevent chemotherapy-induced 
alopecia (CIA)1. (Nangia et al., 2017, Rugo et al., 2017) It is assumed that scalp cooling 
works by inducing vasoconstriction and reduction of metabolism. Vasoconstriction leads 
to reduced blood flow to the hair follicles during the time period of peak plasma 
concentrations of the relevant chemotherapeutic agent. In addition, reduced metabolic 
activity could make hair follicles less vulnerable to the damage of cytotoxic agents. Both 
randomized and nonrandomized studies proof that scalp cooling can prevent CIA. (Breed 
et al., 2011, Grevelman and Breed, 2005, Rugo et al., 2017, Nangia et al., 2017)  
However, comparing or pooling data on the efficacy of scalp cooling between studies has 
been complicated by the lack of a standardized methodology to evaluate hair loss. (Van 
Neste, 1999, Van Neste, 2002, Chamberlain and Dawber, 2003, van den Hurk et al., 
2015) 
Methods to measure the severity of chemotherapy-induced hair loss can be 
categorised as invasive, semi-invasive and non-invasive. Invasive and semi-invasive 
measurements like scalp skin-biopsies and hair root analysis are objective, but can be 
unpleasant for patients and are costly and time consuming. (Chamberlain and Dawber, 
2003, Van Neste, 2002, Van Neste, 1999, Canfield, 1996, Donati et al., 2011) Non-
invasive techniques like photography or counting shed hairs could also be useful in 
assessing the severity of hair loss. (Chamberlain and Dawber, 2003, Van Neste, 2002, 
Donati et al., 2011, Massey, 2004, Peck et al., 2000, Ridderheim et al., 2003) 
Photography may be used to compare the difference in visible hair loss during treatment, 
but it is subjective and does not generate a reliable estimation for hair loss on a localized 
area of the scalp. Hair counts do generate a quantitative value, although they also do not 
provide information about hair loss on a localized area of the scalp. (Cohen, 2008) In 
scalp cooling studies, several widely accepted subjective scales have been used to assess 
hair loss, such as the World Health Organisation (WHO) classification of chemotherapy-
induced alopecia (World Health Organisation, 1979), the Common Terminology Criteria 
for Adverse Events (CTC-AE) (U.S.Department of Health and Human Services, 2009) or 
Visual Analogue Scale (VAS) (Ridderheim et al., 2003) In addition, other measurements 
like Dean’s alopecia scale (grade 1: <25% hair loss; grade 2: 25%-50% hair loss; grade 
3: 50%-75% hair loss, grade 4: >75% hair loss), various Likert scales (rating scales) 
and pictorial assessments have been described in literature on scalp cooling. (van den 
Hurk et al., 2015) For study purposes, there is a need for an operator- and patient 
friendly, inexpensive, and validated method for measuring hair quantity. Until recently 
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there was no reliable, simple method available to measure hair quantity in an objective 
way, but in recent years the Hair Check method has become available. (Cohen, 2008) 
The Hair Check is a mechanical device that compresses a bundle of hair in a disposable 
cartridge from a delineated area of the scalp and measures its cross-sectional area. In 
this way, the amount of hair (in mm2) per unit of scalp skin area (in cm2) (Hair Mass 
Index, HMI)2 can be defined. (Hendriks et al., 2012) In a study to test the clinical utility 
of the Hair Check in healthy volunteers it was concluded that measurements were simple 
to perform, and data showed high reproducibility. (Hendriks et al., 2012) We therefore 
decided to investigate the correlation between patient reported outcome assessments 
and the quantitative method of HMI measurement to assess the amount of hair loss in 
patients treated with chemotherapy. In addition, we studied the correlation between the 
opinion of patients, doctors, nurses and hairdressers assessed with subjective methods.  
 
PATIENTS AND METHODS  
Patients 
The study enrolled patients with primary invasive breast cancer without distant 
metastasis planned for treatment with three to six cycles of combination chemotherapy 
at 3-weekly intervals with FEC (5-fluorouracil, epirubicin, cyclophosphamide) or AC 
(adriamycin, cyclophosphamide). Subsequent chemotherapy cycles consisting of 
docetaxel monotherapy were allowed after 3 FEC cycles. Patients were excluded if they 
lacked basic proficiency in Dutch, if they were unable to understand the patient 
information brochure or if they suffered from cold sensitivity, cold agglutinin disease, 
cryoglobulinemia, cryofibrinogenemia or cold posttraumatic dystrophy.  
 
Study design 
We conducted an explorative prospective single-centre study between August 2010 and 
January 2014 at the department of Internal Medicine of the Medical Centre Alkmaar, the 
Netherlands. At baseline, patient characteristics were collected. Before the start of the 
chemotherapy, patients were asked to rate their hair quantity (much, moderate, little 
hair).  
Objective hair quantity was measured with a Hair Check before each 
chemotherapy cycle (table 1). The mechanical device compresses a bundle of hair in a 
disposable cartridge from a delineated area of the scalp and measures its cross-sectional 
area. HMI incorporates both density and diameter and was measured at both temporal 
sides. (Cohen, 2008) The validity of the device was tested using bundles of hair and 
surgical silk fibres. It showed a high degree of precision and it was concluded that the 
device could be used as a reliable substitute for the methods that are presently used to 
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measure hair loss.(Cohen, 2008) Hendriks et al. designed a study to test the clinical 
utility and reproducibility of the Hair Check. Data in this study showed high 
reproducibility. For intra-observer reproducibility, the mean difference was .2 (95% 
confidence interval (CI)= -4.7-5.1, correlation coefficient (r) =.99). For interobserver 
reproducibility, the mean difference was -.4, 95% CI = -8.0-7.2, r=.97. (Hendriks et al., 
2012) To define the measuring location, a location strip was used and marked using a 
four-legged marking template moistened with red ink (figure 1). The hair bundle within 
this marked area was measured using the Hair Check.  
 













1       little hair 





No hair loss      total hair loss 
Subjective Ordinal:  0-10 Cycle 2-6 
WHO classification 19 
0 No change 
1 minimal hair loss 
2 moderate, patchy alopecia 
3 complete alopecia, but 
reversible 
Subjective Ordinal:  0-3 Cycle 2-6 
Head covering 
       Yes/ no 
Subjective Nominal: Yes/ no Cycle 2-6 
*HMI: Hair Mass Index 
**VAS: Visual Analogue Scale 
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Figure 1. The use of the hair check 
   
 
Before cycle 2, patients evaluated the severity of alopecia on the 4-point scale 
(range 0-3) for alopecia of the World Health Organisation (WHO) (World Health 
Organisation, 1979) and by using a VAS for hair loss (range 0-10, 0 = ‘No hair loss’, 10 
= ‘Total hair loss’). The success of scalp cooling was defined in terms of the patient’s 
self-determined need to wear a wig or other head covering to mask visible hair loss after 
chemotherapy treatment (table 1). To assess hair loss by photography, a protocol was 
designed to standardise camera settings to depict various degrees of hair loss. Five 
digital images at standard views from frontal, vertex, occipital and both temporal sides 
were made before start of chemotherapy and before the 4th and 6th or last chemotherapy 
cycle. Images were kept in the medical records. Doctors, nurses and hairdressers were 
asked to rate the visible hair loss as depicted on pictures of the patients according to the 
WHO and VAS scores. They assessed the same images twice. Mean scores of the two 
assessments were used and the mean scores of the doctors, nurses and hair dressers 
were calculated. End points were the mean VAS scores of cycle 4 and cycle 6.  
Tolerance of scalp cooling was measured during all visits by a Visual Analogue 
Scale (VAS) of 0-10, in which 0 represented ‘Not tolerable’ and 10 meant ‘Very well 
tolerable’. Patients were considered evaluable for hair preservation if they were treated 
with at least three cycles of chemotherapy or if they discontinued scalp cooling due to 
severe hair loss.  
The study was approved by an independent ethics committee and institution 
review board. All procedures were conducted in accordance with the 1964 Helsinki 
declaration and its later amendments. Specialised oncology nurses informed patients 
about the study. Written informed consent was obtained from all individual participants 
included in the study.  
 
Scalp cooling 
All patients used the one-person cooling machine (PSC-1) of Paxman. The cap was 
applied according to the instructions for use in the nursing protocol. The temperature of 
the coolant in the refrigeration tank was -10°C. This temperature is a standard set up 
performed by the manufacturer. The pre-cooling time was 30 minutes before the start of 
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the chemotherapy infusion. The cool cap remained on the scalp during the infusion 
period, being 60 minutes as a standard, and during 90 minutes afterwards. Scalp cooling 
was applied during all planned cycles of chemotherapy, unless the patient decided to stop 
the cooling procedure based on hair loss, side-effects or for other reasons.  
 
Statistical analysis  
All tests of significance were two-sided, and differences were considered statistically 
significant when p<0.05. All tests were performed using SPSS software (version 20.0) for 
Windows XP. Data was collected using standard forms, which were compiled into a SPSS 
database. The analyses were carried out on all evaluable patients. Descriptive statistics 
were performed to describe the socio-demographic and clinical-related characteristics of 
the study sample. Spearman’s rho rank correlation was used for measuring the 
association between the objective and subjective measurements and between the 
patients, doctors, nurses and hairdressers opinion.  
 
RESULTS  
Patient and treatment characteristics 
Sixty-two female Caucasian patients with breast cancer were included in this study. 
Patient characteristics are listed in table 2. The median age of the patients was 60 years. 
All patients were treated conform the study protocol, for a median of three cycles of 
chemotherapy and scalp cooling (range 1-6). The median duration of scalp cooling was 
195 minutes per cycle. All patients were evaluable for hair preservation and tolerance. At 




Table 2. Patient characteristics (n=62) 





Patients included 62  13 (21%) 49 (79%) 
Median age, years (range) 60 (32-74)   
Epirubicin 50 (81%) 8 (16%) 42 (84%) 
  6x F500/E100/C500 28 (45%) 5 (18%) 23 (82%) 
  3x F500/E100/C500 followed by     
  3xT100 
    Overall 3xFEC, 3xT 
    Result after 3xFEC 








Adriamycin 12 (19%) 5 (42%) 7   (58%) 
  4x A60/C600 10 (16%) 4 (40%) 6   (60%) 
  6x A60/C600dd 2    (3%) 1 (50%) 1   (50%) 
Median number of cycles with scalp 
cooling (range) 
3   (1-6)   
F: 5-fluorouracil; E: Epirubicin; C: Cyclofosfamide; A: Adriamycin; T: Docetaxel 
dd: every two weeks 
 
Baseline hair quantity 
Forty-one percent of the patients reported their hair quantity prior to chemotherapy as 
moderate (scale: much, moderate, little).  
 
Patient-reported success of scalp cooling 
- Head covering yes/no 
Thirteen out of 62 patients (21%) did not wear a wig or head cover at the end of 
anthracycline chemotherapy, despite some slight hair loss.  
- VAS 
Median VAS scores for hair loss increased from 4.1 (range 0-10) after the 1st cycle to 
5.8 (range 0-10) at the 6th cycle. Patients who did not need a head covering had a 
significantly lower median VAS score for hair loss (VAS: 2.3 versus 5.8; p<0.0001) 
(Figure 2). 
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                 N=      62            59           36            27           26            19 
 
- WHO 
Median WHO scores for hair loss were 2 (range 0-3) after cycle 1 and at cycle 6. 
Overall, the median WHO score in patients who did not need a head covering was 
significantly lower than in patients who needed a head covering (WHO: 1 versus 2; 
p<0.0001) (figure 3). Hair loss assessed with VAS and WHO demonstrated a strong 
correlation (ρ= 0.7).  
 
Figure 3. World Health Organisation (WHO) scores for patients with and without head covering during 6 cycles 
chemotherapy (P<0,0001) 
                   
                 N=         62                 59                36                27                26                19 
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HMI 
Hair Check measurements at the left and right side of the head did not show significant 
differences, except for cycle 4. Since there is no rationale for these differences, they 
were reported as the mean of the two temporal measures. The mean baseline HMI was 
64 (range 24-100) and decreased to 25 (range 6-53) in the 17 patients who were 
evaluable after 6 cycles (table 3). HMI decreased throughout all cycles of chemotherapy, 
but the highest decrease was seen after the second cycle (figure 4). Baseline HMI 
correlated with patient-reported baseline hair quantity, but was not predictive for hair 
loss (HMI no head covering 61; HMI head covering 64; p=0.7). HMI did not correlate 
with VAS and WHO during therapy (HMI-WHO: ρ= -0.4; HMI-VAS: ρ= -0.4). Patients 
who did not need a head covering had a higher median HMI score (HMI: 51 versus 43; 
p=0.034) (Figure 5). 
 





















Figure 4 Hair Mass Index (HMI) during six cycles chemotherapy  
 
 









1  59 64 2.5 24-100 
2  41 54 3.2 13-95 
3 28 44 4.0 15-84 
4 26 39 3.9 9-73 
5 25 35 4.0 10-80 
6 17 25 3.7 6-53 
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    N=      59             41            28            26            25           17 
 
 
Healthcare professional evaluation of hair loss-photography 
There was a strong correlation of the VAS scores of hair loss, as measured by doctors 
and nurses (ρ=0.84). The correlation between the opinion of health care professionals 
(doctors and nurses) and the opinion of the patients was moderate (VAS: ρ=0.50-0.56 
respectively). However, the opinion of the hair dressers matched strongly with the 
opinion of the patients with respect to hair loss measured with VAS (ρ=0.70) (table 4). 
 
Table 4. The association between the VAS-scores of patients and professionals   
 Nurse Doctor Hair dresser Patient 
Nurse - 0.84** 0.83** 0.56** 
Doctor - - 0.80** 0.50** 
Hair dresser - - - 0.70** 
Patient - - - - 
** = sig. at 0.01 level 
 
Tolerance and safety analysis 
Scalp cooling was very well tolerated. The VAS score for the tolerance of scalp cooling 
was performed over 192 cooling sessions, resulting in a mean score of 8 (SD: 1.9). Only 
one patient stopped scalp cooling because of intolerance after cycle 4. No scalp 
metastases were reported during follow up. 
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DISCUSSION  
This study investigated the value of the Hair Check to measure chemotherapy-induced 
hair loss in patients treated with anthracycline-containing combination chemotherapy. 
Initial hair mass as measured by the Hair Check correlated with patient-reported hair 
quantity before the start of the chemotherapy, but was not predictive for the severity of 
hair loss during scalp cooling. Thus, it seems that the efficacy of scalp cooling in 
preventing CIA is independent of having either thin or thick hair. This adds to our 
knowledge that the efficacy of scalp cooling mainly depends on the type and dose of 
chemotherapy, and the degree and duration of scalp cooling. (Komen et al., 2013) 
Unfortunately, we do not have data on the Hair Check during scalp cooling in Asian or 
Afro-hair patients. 
It is noteworthy that, according to the Hair Check, hair loss continued throughout 
six chemotherapy cycles, although patients themselves did not report any increase in 
hair loss (as measured with VAS for hair loss) after cycle 4 (figure 6). Obviously, HMI is 
more sensitive for detecting subtle changes in hair loss than subjective measurements. 
Therefore, to improve the efficacy of scalp cooling, efforts should be made to increase its 
efficacy throughout the complete time span in which all cycles of chemotherapy are 
administered. Hair mass as measured by the Hair Check did not correlate with patient-
reported outcome assessments such as WHO and VAS score. Therefore, it is not useful as 
a clinically relevant endpoint for hair loss, while it is time consuming in daily practice as 
well (about 15 minutes per measurement). 
 
Figure 6 Visual Analogue Scale (VAS) score during six cycles chemotherapy 
 
                 N=          59                     36                    27                    26                     19 
 
 87 
The opinions of hair loss of health care professionals correlated only moderately 
with those of patients, but the opinion of hair dressers was more in line with the patients. 
Apparently, due to their professional experience hairdressers are better capable to 
estimate hair loss than healthcare professionals are. The weak correlation between 
patients and health care professionals demonstrates that the patients’ opinion of hair loss 
should be considered as the best subjective method to assess the efficacy of scalp 
cooling. In some clinical studies on CIA hair loss is measured by clinicians (Nangia et al., 
2017) or nurses (Lemenager et al., 1997, Massey, 2004), but our study confirms the 
findings of Mulders et al. (Mulders et al., 2008) that healthcare professionals 
underestimate the severity of hair loss. 
This study has some limitations. Firstly, the sample size was limited. The study 
may have been underpowered to detect differences between the methods of evaluation. 
Secondly, we did not prescribe a standardized hair care at the day of measuring HMI. 
Possibly, the use of styling products could have slightly influenced HMI, but before 
standardized hair care might be prescribed, the exact influence has to be examined. 
Thirdly, we delineated the measured location by using a location strip. The use of this 
strip can cause slight deviations in retrieving the exact measuring location every cycle. 
However, Vleut et al. (Vleut et al., 2013) showed that a slight deviation of the 
measurement area caused no significant deviations in HMI. 
In a large registry study on scalp cooling 33% and 39% of patients treated with 
FEC or AC chemotherapy, respectively, did not need a head covering. (van den Hurk et 
al., 2012) In this study, only 21% of patients was successfully treated with scalp cooling 
to prevent CIA. The low efficacy in the present study might be explained by the fact that 
patients decided to stop scalp cooling because they were more aware of the continuous 
hair loss during chemotherapy as measured by the Hair Check and subjective registries.  
We measured HMI at both sides of the head, because the gradation of hair loss in 
a balding individual was found to be much higher along the sagittal axis than the coronal 
axis. (Cohen, 2008) According to our results, HMI measurements at the left and right 
side of the head did not show significant differences; therefore we recommend HMI 
measurement at one side for future research. However, in daily practice we advise to 
preferably use a generally accepted and practical subjective scale for hair loss such as 
WHO or VAS. 
Although it was confirmed that WHO and VAS correlated strongly (ρ= 0.7), the 
latter is more sensitive for small changes in hair loss and therefore more valuable to use 
when comparing different groups of patients. In addition, to evaluate hair loss in clinical 
practice, the use of a wig or head cover can be considered as a parameter for patient 




Initial hair mass index (HMI) as measured by the Hair Check correlated with patient- 
reported hair quantity before the start of the chemotherapy, but was not predictive for 
the severity of hair loss during scalp cooling. It seems that the efficacy of scalp cooling in 
preventing CIA is independent of having either thin or thick hair. According to the Hair 
Check, hair loss continued during all chemotherapy cycles.  Therefore, to improve the 
efficacy of scalp cooling, efforts should be made to increase its efficacy throughout the 
complete time span in which all cycles of chemotherapy are administered. The weak 
correlation between patients and health care professionals demonstrates that the 
patients’ opinion of hair loss should be considered as the best method to assess the 
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Purpose: Chemotherapy-induced alopecia (CIA) is generally considered as one of the 
side-effects with the most impact for patients. To explore the pathobiology of CIA and to 
improve the efficacy of scalp cooling in preventing CIA, it is important to analyse the 
molecular damage-response pathways in human hair follicles during and after 
administration of chemotherapy. We report a single centre explorative pilot study. 
Objectives: The objective of this study was to explore damage-response pathways in 
hair follicles after chemotherapy. 
Methods: Hair follicles were collected from ten patients with breast cancer who were 
planned for treatment with anthracycline-based combination chemotherapy without scalp 
cooling. Hair follicles were collected before and at different time points after 
chemotherapy administration and subsequently embedded in methyl-methacrylate. 
Haematoxylin and eosin (H&E) staining was used to analyse the sections for apoptotic 
cells. These sections were stained with immunohistochemical antibodies.   
Results: Hair follicles were successfully processed according to the protocol. 
Morphological signs of apoptosis were detected at different time points. 
Immunohistochemical staining could be successfully carried out in most of the sections. 
Cells staining positive for p53, caspase-3 and ki-67 could be detected in the hair shaft 
and the hair bulb. We were not successful in obtaining sufficient numbers of evaluable 
hair bulbs and therefore could not generate reliable data on markers of apoptosis in the 
ten treated patients. 
Conclusions: These findings stimulate further development of methods to use hair 
follicles collected from patients as a human-based model for exploring the working 




Cancer treatment with cytotoxic agents is associated with severe side effects. 
Chemotherapy induced alopecia (CIA) is one of the most distressing side effects for many 
patients(1,2) and begins days to weeks after the administration of chemotherapy.(3,4) 
Chemotherapy interferes with proliferating cells causing cell death or preventing cell 
growth, but the exact underlying pathobiology of CIA remains insufficiently 
understood.(3-12) In normal life, the growth cycle of a hair follicle consists of three 
phases: the anagen, catagen and telogen phase. The hair growth (anagen) phase 
involves the growth of a hair from a hair follicle and lasts for three to seven years. During 
the transitional (catagen) phase (2-3 weeks), the hair follicle atrophies and migrates 
upwards in the skin. During the resting (telogen) phase (3-4 months), the hair does not 
grow but stays attached to the hair follicle. The telogen phase ends when the old hair is 
shed and a new hair is regenerated in the anagen phase.(13,14) Since 90% of all hair is 
in anagen phase and rapidly proliferates, hair follicles are highly at risk to be affected by 
chemotherapy, resulting in CIA. The most characteristic response of a hair follicle to 
chemotherapy is an anagen effluvium (shedding of hair follicles in the growth phase). 
Telogen effluvium also occurs, characterized by increased proliferative activity, 
presumably as a repair strategy, resulting in diffuse CIA.(15)  
Research models for investigating molecular mechanisms of CIA are depicted in 
Table 1. At present, research in rodent and ex-vivo models is used to explore the 
pathobiology of CIA and to test novel management strategies in the prevention of CIA.  
However, these models have limitations in studying the direct effect of interventions on 
human hair follicles treated with chemotherapy. In rodent models, such as mouse or 
neonatal rat models, it was found  that hair follicle apoptosis largely depended  on p53, a 
key mediator of cellular damage caused by a  stress response.(15) However, the clinical 
relevance of rodent hair follicle models is limited because they do not reflect the cycling 
rhythm of hair follicles in human beings. Research models with ex vivo cultures of human 
hair follicles enable direct testing of the damaging effects of defined cytostatic 
agents.(16-18) Al-Tameemi et al. confirmed with their ex-vivo model that cooling 
reduced or completely inhibited drug cytotoxicity in human keratinocytes exposed to 
chemotherapy, supporting the hypothesis of scalp cooling.(17) However, keratinocytes in 
this model are not in cycle and begin to degenerate after 1-2 weeks in culture. Moreover, 
it is difficult to imitate the application schedule of standard chemotherapy regimens as 
human hair follicles damaged by chemotherapy will still be in the recovery phase when 
they are exposed to the next cycle of chemotherapy. Botchkarev demonstrated that in 
contrast to wild-type mice, p53-deficient mice show neither hair loss nor apoptosis in the 
hair follicle keratinocytes after cyclophosphamide treatment.(13) Hendrix et al. and Paus 
et al.(15,19) showed in mice that hair follicles undergo two distinct pathways of 
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dystrophy (dystrophic anagen and dystrophic catagen pathway) after chemical damage. 
During the so-called dystrophic anagen pathway (induced mainly by a lower dose of 
chemotherapy), the hair follicle undergoes an incomplete primary recovery followed by a 
retarded secondary recovery during which a normal hair shaft is generated. Hair follicles 
that undergo the dystrophic catagen pathway (in response to a higher dose of 
chemotherapy) immediately enter into a dystrophic catagen stage, followed by an 
abnormally shortened telogen phase. Scalp cooling, possibly forces hair follicles into the 
dystrophic anagen phase, thereby enabling patients to keep their hair. Two hair follicle 
damage response pathways (dystrophic anagen and dystrophic catagen pathway) were 
also reported in a research model of surgical grafting of human hair follicles on 
immunodeficient mice .(13,15,20) Unfortunately, this technique still does not 
demonstrate the direct effect of treatment with chemotherapy in hair follicles of patients. 
Randall et al.(21) reported a method for the fixation, processing, sectioning and 
immunohistochemical staining on plucked human hair, which allows monitoring of the 
effects of anti-cancer drugs on cell proliferation Ki -67) and on the upstream signaling 
molecules that control cell proliferation (p53/ Caspase-3).  
So far, there is no effective preventive pharmacological therapy for CIA. 
Management of CIA primarily consists of counseling, professional psychological support 
and the recommendation to use a wig when hair loss occurs.(14,22,23) Scalp cooling is 
the only intervention to prevent CIA, its efficacy depending on the type and dose of 
chemotherapy. It is assumed that scalp cooling reduces skin temperature, thereby 
affecting the exposure and metabolism of cytotoxic agents in the hair follicles.(9,24) In 
vitro models showed that cooling markedly reduced cytotoxicity, in agreement with 
clinical observations.(17) Sakurai et al. examined the effects of low temperature (32 
degrees C) on cells exposed to cytotoxic agents in vitro. (25) Mild hypothermia 
suppressed induction of apoptosis by p53-dependent and p53-independent mechanisms. 
P53 activates downstream apoptotic events, leading to a cascade of activation of 
caspases, including Caspase-3, which induces apoptosis.(26) Ki-67, a cellular marker for 
proliferation, is down regulated in hair follicles showing apoptotic changes(20), and is 
therefore an interesting marker in research discovering the mechanism of scalp cooling. 
Plucked human hair may offer a minimally-invasive, easily sampled and well-
tolerated source of hair follicle cells for the investigation of damage response pathways in 
patients treated with chemotherapy. In order to improve scalp cooling and to develop 
new treatment strategies for the prevention of CIA, we set out to explore molecular 
damage-response pathways in plucked human hair from patients treated with 
chemotherapy.   
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Rodent models (neonatal 
rats and adult 
mice)(19,27,28)  
Rodent models permit 
investigation of how 
chemotherapy affects the 
hair follicle cycling.  
Similar to in human CIA, 
hair loss in rodent models 
generally follows specific 
patterns. 
In neonatal rats 
chemotherapy affects hair 
follicles that are still in the 
final stages of postnatal 
morphogenesis. In adult 
mice hair cycling is more or 
less synchronized across all 
follicles, whereas in human 
beings each hair follicle 
follows its own cycling 
rhythm. 
Organ cultured hair 
follicles(16,17,20,29)  
Enables direct testing of the 
damaging effects of 
cytostatic agents and 
provide the most clinically 
relevant surrogate model 
for CIA 
Not possible to investigate 
how chemotherapy affects 
the hair follicle cycling. No 
information about the hair 
loss pattern. 
Surgical grafting of human 
scalp skin on to 
mice(20,28,30)  
Combines benefits of 
human and rodent models. 
Resembles key features of 
CIA that occurs in patients 
with cancer. 
Human hair follicles are 
exposed to a different 
milieu of the mouse 
hormones and local growth 
regulators.  
Hair collection from patients  Minimally invasive 
technique which enables 
direct testing of the 
damaging effects of 
cytostatic agents in human 
hair follicles. 
No available surrounding 
scalp tissue to provide more 
insight in the mechanism of 
action. Very time 
consuming and delicate 
process. 
 
MATERIALS AND METHODS 
We conducted an explorative single centre pilot study at the department of Medical 
Oncology of Northwest Clinics, the Netherlands. Patients with breast cancer who were 
planned for treatment with at least one cycle of anthracycline-based combination 
chemotherapy (docetaxel-doxorubicin-cyclophosphamide(TAC), fluorouracil-epirubicin-
cyclophosphamide(FEC) or doxorubicin-cyclophosphamide(AC)) without scalp cooling 
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were enrolled. Patients were excluded if they lacked basic proficiency in Dutch or if they 
were unable to understand the patient information brochure. The hair follicle analyses 
were conducted at the department of pathology of the University Medical Centre Utrecht. 
The study was approved by an independent ethical committee. All procedures were 
conducted in accordance with the 1964 Helsinki Declaration and its later amendments. 
Written informed consent was obtained from all patients included in the study.  
 
Sampling and fixation 
Patients were asked to collect approximately 30 scalp hairs at six time points after the 
first cycle of chemotherapy. Collection time points were T0= before chemotherapy, 
T3=day 3, T5=day 5, T9=day 9, T13=day 13, T17=day 17 after chemotherapy. The first 
sample collection (T0) took place at Northwest Clinics and was conducted by a research 
nurse. The following five samples were collected by patients at home. Hairs were plucked 
from the parietal region of the scalp using a blunt-nosed forceps. Hairs were stored into a 
tube containing 10% neutral-buffered formalin which was brought home by the patient. 
The tubes were handed in at the next hospital visit. After collection, the hairs were 
checked by a research nurse for the presence of a bulb and stored in phosphate buffered 
saline (PBS) at room temperature at Northwest Clinics and sent to the department of 
Pathology of the University Medical Centre Utrecht for further analysis. 
 
Processing and embedding  
Hairs were trimmed to approximately 1 cm and attached to a small piece of photo 
sticker, enabling parallel embedding of the hairs and simultaneous sectioning of multiple 
hair bulbs. Per photo sticker, five hairs were embedded in 3% low melting point agarose. 
Hairs were horizontally embedded in one agarose block cast in silicone embedding molds. 
The agarose blocks were trimmed to fit in the processing baskets of the Leica EM tissue 
processor. The blocks were processed according to the steps as described by Randall et 
al.(21) After processing, the remaining photo stickers were carefully removed. The 
processed agarose blocks were embedded in 8 mm, flat-ended, embedding capsules filled 
with polymerization solution which consisted of catalyzed MMA plus 125 μl N,N-
dimethylaniline. The blocks were orientated longitudinally at the bottom of the 
embedding capsules. To keep the blocks from floating upward after adding the 
polymerization solution, a horizontally placed shortened pipette tip was gently pushed 
onto the block. The capsules were then placed in a desiccator at room temperature to 
flush out the oxygen-free nitrogen for approximately 2,5h during the polymerization of 





The polymerized blocks were kept in capsules for another 24 hours at room temperature. 
When removed from the capsules, the plastic blocks were stored at room temperature 
before sectioning. The blocks were cut in 2 μm-thick sections on a Leica Ultracut 
Microsystems microtome (Cell Microscopy Core, Department of Cell Biology at the UMCU) 
using a glass knife. The sections were picked up with a fine-nose forceps and spread out 
on a droplet of water on a glass slide. The slide was then transferred to a hotplate to 
flatten the section out. A toluidine blue staining was performed to confirm the presence 
of hair follicles in the section. After sectioning, the slides were stored in a refrigerator.  
 
Preparation of slides and Haeamatoxyline and Eosine staining (H&E)  
Processed sections were microscopically analyzed and assessed for evaluability. Prior to 
H&E staining, the slides were incubated at 37°C for approximately 3 hours, followed by 
overnight deplasticising in xylene at room temperature. Sections were rinsed twice in 
xylene, three times in 10% methylated spirit, once in 100% ethanol and once in 70% 
ethanol, before hydration in distilled water. The sections were H&E stained by incubating 
in haeamatoxylin for 10 minutes and in eosin for 2 minutes. After dehydration, slides 
were mechanically cover slipped in pertex. H&E stained hair bulbs were analyzed for the 




Slides were treated by blocking in 3% hydrogen peroxide for 15 minutes. After being 
rinsed in distilled water, heat-mediated antigen retrieval took place in an autoclave at 
125 ◦C in EDTA, pH 9.0, and cooled down for 20 minutes. IHC staining was performed 
using the following antibodies: Ki-67 (Dako, clone MIB-1, 1/100), P53 (Dako, clone Do7, 
or 1/500) and anti-active caspase 3 (Pharmingen Purified rabbit 1/500). Primary 
antibodies were incubated at room temperature for 1 hour. For p53 and Ki-67 staining, 
slides were treated pre-and post- antibody incubation with the Novolink kit (Leica, NL). 
Active caspase 3 staining was treated with the Novolink kit, Bright Vision poly AP-Anti 
rabbit IgG and Dako liquid permanent red. After counterstaining with haeamatoxylin for 
10 seconds, the sections were dehydrated and mechanically cover slipped in pertex. The 
material was assessed microscopically for evaluability of apoptotic cells. Appropriate 
positive and negative controls were taken along each staining and consisted of formalin 





Data were collected using standard forms, which were compiled into a database. Due to 




Between January 2013 and November 2014, ten patients treated with anthracycline-
based chemotherapy were included to explore the best time points for hair collection and 
to optimise the fixation, embedding and staining protocol. Patient characteristics are 
shown in table 2. The median age of patients was 48 years and all patients were treated 
for breast cancer. Eight patients were evaluable for hair root analysis after T0. Two 
patients had not collected hairs at home because of sickness. 
 
Table 2. Patient characteristics  
 N 
Patients included 10 
Patients evaluable for hair root analysis 8 
Median age, years (range) 48 (35-57) 
Chemotherapy 
     FEC 
     TAC 







Processed sections were microscopically analyzed and assessed for evaluability. Hair 
follicles collected are shown table 3. At T0 a total of 61% of collected hair samples was 
evaluable for analysis. Non-evaluable sections were seen in 39% of the samples and 
contained hair remnants with or without attached connective tissue or without the 
presence of any hair follicle epithelium (Figure 1). Unfortunately, a sharp decrease of 
evaluable hairs was detected over time. At T17 none of the hair follicle samples were 
evaluable, only hair shafts or connective tissue could be identified. 
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Table 3. Hair follicles collected at various time points  
 T0 T3 T5 T9 T13 T17 
No. Patients 
collecting hairs 
10 8 7 6 6 2 





20 18 14 12 12 6 
% Evaluable hair 
follicles 
86% 94% 57% 42% 17% 0% 
No. Apoptotic 
cells in evaluable 
hair follicles 
8 0 2 2 1 0 
T0: Before the start of chemotherapy 
T3: Three days after chemotherapy 
T5: Five days after chemotherapy 
T9: Nine days after chemotherapy 
T13: Thirteen days after chemotherapy 
T17: Seventeen days after chemotherapy 
 




Results of hair root analysis demonstrated the presence of a low frequency of apoptotic 
cells, characterized by cellular shrinkage, eosinophilic cytoplasm and nuclear 
fragmentation. Apoptotic cells, found at different time points, seemed to be preferentially 
located in the root sheath. Isolated apoptotic cells were found as well as areas with 
several apoptotic cells (Figure 2). The highest amount of apoptotic cells was observed at 
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T0 and decreased after chemotherapy. In some sections, pink artefacts were present 
(Figure 3), probably representing dislocation of parts of the inner root sheath resulting 
from overstretching of the hair follicle when pulling out.  
 



















Immunohistochemical staining was exploratively performed in samples of four patients in 
whom histochemical sections showed the best quality. P53 and Ki-67 staining showed 






Figure 4. P53 staining (a: T=1, b: T=5) 
  
 
Figure 5. Ki-67 staining (a: T=1, b: T=5) 
  
 
Ki-67 IHC showed a decreasing brown diaminobenzidine (DAB) precipitate from core to 
shaft, following the normal proliferation rate of cells in hairs. Samples stained with active 
caspase 3 antibody showed little positive cytoplasm at T0, mainly in the bulbus section 
(Figure 6).  
 








This study shows results of hair follicle analyses in patients treated with chemotherapy. 
We optimised the fixation, embedding and staining protocol of hair follicles from patients 
and explored signs of apoptosis at various time points after chemotherapy. We 
hypothesized that we could detect signs of apoptosis after chemotherapy administration 
and it was our intention to confirm this hypothesis in a larger study.  
Unexpectedly, as is depicted in table 3, we found a decrease of evaluable sections of hair 
follicles and shafts over time after administration of chemotherapy. Therefore, we 
decided to shorten the time interval between hair root analysis in a second group of 
patients.  
Between March 2017 and April 2018 another twenty patients with or without scalp 
cooling were studied in a similar way to explore the molecular damage-response 
pathways in human hair follicles after chemotherapy. However, the process of 
embedding, cutting and coloring was very complicated and time consuming, and there 
were not enough evaluable hair bulbs for analysis in these 20 patients. 
We identified several reasons which can explain why we were unable to confirm our 
hypothesis (Table 4).  
 
Table 4. Limitations and recommendations 
Influencing factor Limitation Recommendation for future 
research 
Collection of hairs Only hair follicles were 
collected 
Take skin biopsies to collect 
surrounding scalp tissue 
Selection of hairs Hairs were collected by the 
patient themselves 
Controlled collection by an 
experienced nurse and 
preselection of hairs with a 
preparation microscope 
Fixation period Long fixation period could 
affect the material 
Fixation of hair samples 
maximal 4 hours 
Sectioning protocol Complicated protocol and 
very delicate sectioning 
process  
3-D scanning or Microscopy 
with Ultraviolet Surface 
Excitation (MUSE) 
 
Firstly, hair follicles were collected using a blunt nose forceps. Preferably we would have 
taken scalp skin biopsies from patients treated with chemotherapy. By collecting 
surrounding scalp tissue, the effect of chemotherapy on the surrounding skin could have 
given us more insight into the mechanisms of action. However, when patients have no 
direct treatment benefit, performing biopsies presents a difficult ethical issue. Due to 
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these ethical problems, we explored the possibilities to perform immunohistochemical 
staining on hair follicles directly collected from the patient’s scalp. Secondly, the yield of 
hairs could have been improved by a controlled method for pulling out hairs, and by a 
preselection of hairs with sufficient follicle epithelium for analysis with a preparation 
microscope.  
Thirdly, the long fixation period of the hair follicles might have caused a disadvantage. 
According to Randall et al.(21) the optimal period of fixation appears to be 4 hours at 
room temperature. To prevent patients from daily travelling to the hospital to deliver 
their collected hair samples, the samples were brought to the hospital with the next 
scheduled appointment. This considerably delayed the period of fixation but had no 
negative effect on the morphology of the hair follicles. However, immune histology had to 
take this into account in the degree of antigen retrieval. Unfortunately, hair follicle 
research turned out to be a very delicate process and depended too much on the 
availability of dedicated people. The method of fixation according to Randall et al. was 
difficult to reproduce and we failed in making a robust model for large scale analysis of 
hair bulbs. The procedure was too time consuming and despite all effort, too much tissue 
was not evaluable (figure 7). For a better understanding of the working mechanism of 
CIA, the method as described by Randall et al. may not be the best option. Solid 
methods which consistently and reliably can demonstrate molecular damage response 
pathways are needed.  
 
Figure 7. Non-evaluable hairs due to complicated sectioning  
  
 
There are some important developments which could be helpful. Multiple hairs 
could be embedded in an upright position and close to each other to be cut in series and 
to create a 3-D reconstruction through scanning. This technique enables visualizing the 
entire hair follicle and suffers less from different levels of depth. Another possibility is the 
use of Microscopy with Ultraviolet Surface Excitation (MUSE), which uses ultraviolet light 
to illuminate tissue samples. Commonly used bright-field microscopy requires prior 
preparation of tissue sections mounted on glass slides, a process that can require hours 
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or days. The UV microscope removes the need for performing traditional histology and 
produces high-resolution images of biopsies and other fresh tissue samples within 
minutes.  
A dedicated analytical staff is needed to handle the hair bulbs during the whole 
process of plucking, preservation, sectioning and staining in order to obtain sufficient 
slides to perform analysis and to draw conclusions. 
 
CONCLUSION 
The aim of this study was to explore molecular damage-response pathways in hair 
follicles from patients treated with chemotherapy. We found that H&E and 
immunohistochemical staining was possible on a number of embedded hair follicles. 
Unfortunately, we were not successful in obtaining sufficient numbers of evaluable hair 
bulbs and therefore could not generate data on markers of apoptosis in treated patients. 
However, better and standardized techniques for sampling and analyzing of hair bulbs 
are needed to study the damaging effects of cytostatic agents and to test new potential 
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GENERAL DISCUSSION  
 
Efficacy of scalp cooling 
Scalp cooling is increasingly being used in the prevention of chemotherapy-induced 
alopecia (CIA) in patients treated for cancer. Although a substantial number of patients 
does not suffer from CIA, scalp cooling is still not effective in all chemotherapy regimens 
and there is a subset of patients who has no beneficial effect from scalp cooling. 
Improvement of scalp cooling is therefore necessary as well as a better selection of 
patients who will likely benefit from it. To improve scalp cooling we focused on post-
infusion cooling time and scalp skin temperature, two possible factors to improve 
outcomes. We also tried to analyse the molecular damage-response pathways in human 
hair follicles during and after administration of chemotherapy. Clarifying the working 
mechanism could help to improve scalp cooling and could be used to develop new 
treatment strategies for the prevention of CIA. 
 
Adapting post-infusion cooling times 
Determining the most optimal post-infusion cooling time has practical implications for 
scalp cooling in clinical practice. The most optimal post-infusion cooling time is unknown 
for many chemotherapy regimens. Is it ‘the longer the better’, or could it be shortened 
for patient comfort and for logistic reasons? The optimal cooling time for scalp cooling 
has not been studied extensively.(1,2) 
We decided to investigate the post-infusion cooling times after treatment with low 
dose docetaxel (75 mg/m2 every three weeks) and after combination therapy with 5-
fluorouracil, epirubicin and cyclophosphamide (FEC). In the low dose docetaxel regimen, 
scalp cooling is very effective (73% of patients do not require a wig)(3) and a short post-
infusion cooling time (20 minutes) turned out to be just as effective as a long time (45 
minutes).(2) In contrast, prolonging cooling time the FEC regimen (150 versus 90 
minutes), in which scalp cooling is less effective (56%)(3), did not improve outcome 
significantly.(4) As the procedure of scalp cooling has to be feasible in daily practice, we 
decided that the small non-significant difference in effectiveness in our study with cooling 
times until 150 minutes did not justify further studies with even longer post-infusion 
cooling times.  
Whereas shortening of the post-infusion scalp cooling time did not show 
differences in scalp cooling effectiveness in patients treated with low dose docetaxel, 
better results of scalp cooling were observed with the lower weekly docetaxel dose in 
comparison with the higher three weekly docetaxel dose. These findings are in line with 
the findings of Al Tameemi et al. who showed dose-dependent cytotoxicity in their in 
vitro model.(5) Apparently, the peak concentration of a cytostatic agent is more 
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important in determining toxicity than the exposure over time to chemotherapy. It is 
likely that individual variation in the efficacy of scalp cooling is due to interpatient 
variability in chemotherapy pharmacokinetics and peak drug concentrations. 
It would be interesting to investigate short (20-minute) post-infusion cooling 
times in other chemotherapy regimens in which scalp cooling is used successfully (for 
example, all regimens with >70% effectiveness in preventing CIA). The so-called 
standard of 90-minute post-infusion cooling time has been chosen arbitrarily with the 
introduction of scalp cooling in the Netherlands. A possible explanation for protecting hair 
follicles even with shorter cooling times could be that the drug is flushed away from the 
hair follicles more rapidly during scalp cooling. Considering this, one might even question 
whether it is possible to omit the post-infusion cooling time.  
 
Scalp skin temperature  
In addition to the differences between individual patients with respect to 
pharmacokinetics of chemotherapy, the optimum scalp skin temperature during scalp 
cooling could also contribute to a better scalp cooling effect. When one wants to 
investigate this, an easy accurate temperature measurement of the scalp skin during 
scalp cooling is necessary. We used temperature probes to record scalp skin 
temperatures during cooling.(6) These measurements were accurate, but they were very 
time consuming and not useful in daily practice. It has been suggested that a scalp skin 
temperature <18°C is necessary for optimal scalp cooling results.(6) It would be 
interesting to investigate whether it is possible to decrease the scalp skin temperature 
below this level in those patients who do not reach this temperature.  
Failing to reach a temperature <18°C did not explain all differences in efficacy in 
our patients. We observed patients with a scalp skin temperature of 13-14°C, without a 
beneficial effect from scalp cooling. Apparently, not all patients will benefit from adapting 
the temperature, but it will obviously be worthwhile to try this in some of them as a next 
step to improve scalp cooling results.  
 
Individualizing scalp cooling 
To improve scalp cooling, it is important to understand the exact mechanism by which 
cooling reduces the risk of chemotherapy induced alopecia. It has been suggested that 
vasoconstriction and reduced cell metabolism are important factors. In addition, the 
process of hair loss during and after chemotherapy might be mediated by specific 
molecular pathways. Understanding these mechanisms enables evaluation of the 
influence of various factors and might be of value to predict the outcome of scalp cooling. 
Van den Hurk et al. concluded in 2012 that type and dose of chemotherapy, infusion 
time, age, gender and type of hair significantly influenced the proportion of head cover 
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use.(3) Schaffrin et al. concluded in 2015 that menopausal status, systemic 
comorbidities, medication, nicotin abuse and hair density could also influence the 
outcome of hair loss prevention.(7) However, determinants of scalp cooling results vary 
considerably.(3,7-9)  
Predicting the outcome of scalp cooling with these or other factors could be 
meaningful in counseling patients in the future. However, at present a prediction can only 
be made based on the type, dose and schedule of chemotherapy. Patients should be 
properly informed on the risk of alopecia and other possible side-effects to decide with 
their oncologist which treatment they will receive, ideally in the process of shared 
decision making. It has been shown that patients who lose their hair despite scalp cooling 
experience additional stress.(10) Therefore, it is important to select patients who will 
likely benefit from scalp cooling and provide them with reliable information about what to 
expect in their specific situation. 
 
Limitations and confounding factors 
The many publications reporting scalp cooling contain conflicting data. The influence of 
various factors such as menopausal status or liver function is unknown(7,11), but could 
have influenced the results. This also applies for the chosen method to measure CIA. In 
research focusing on scalp cooling, it is difficult to put the results in a broader 
perspective, because of the lack of a standardized method to measure the amount of hair 
loss. Scalp cooling studies in The Netherlands generally measure CIA by reporting the 
need to wear a wig or other head covering to mask visible hair loss. In other trials the 
use of the World Health Organization (WHO) classification of chemotherapy-induced 
alopecia(12), the Common Terminology Criteria for Adverse Events (CTC-AE)(13) or 
Visual Analogue Scale (VAS) is reported.(14) We concluded that the patient’s opinion of 
hair loss should be considered as the best subjective method to assess the efficacy of 
scalp cooling. It is recommended to register both the patient’s opinion and the VAS or 
WHO classification to facilitate the comparison of the efficacy of scalp cooling in the 
various scalp cooling publications.(15) 
An important limitation in our research was the small sample size in our studies. 
Therefore, the studies might have been underpowered. This particularly applies to our 
study investigating a longer post-infusion cooling time in the FEC-regimen. It was difficult 
to motivate patients to randomize between 90 and 150 minutes, because patients 
thought 150 minutes post-infusion cooling time would not be tolerated. Although we 
could not exclude a clinical meaningful difference between the two post-infusion cooling 
times, we are inclined to state that it would be more interesting to investigate a shorter 
post-infusion cooling time in regimens with good scalp cooling results (>70%) than to 
repeat studies with longer post-infusion cooling times in a larger sample size.  
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Safety information 
For a long time, there was no reliable information on the safety of scalp cooling in clinical 
practice. This prohibited broad scale implementation of scalp cooling, in particular in the 
United States. Besides, clinicians and nurses doubted the effect of scalp cooling, because 
information from well-organized, properly performed randomized scalp cooling studies 
was lacking.  
Since 2009 important safety data have become available.(16-19) A major 
concerns with scalp cooling was that its use would increase the risk of scalp skin 
metastases. Several reports and multiple reviews (16-19) provided evidence to refute 
any potential risk of worse cancer outcome associated with scalp cooling. 
In 2017 Nangia et al. provided evidence for the positive effect of scalp cooling in a 
randomized clinical trial.(20) Women with stage I to II breast cancer receiving 
chemotherapy with either a taxane an anthracycline or both, were randomized between 
the use of scalp cooling or not. The patients who received chemotherapy with scalp 
cooling experienced significantly more often <50% hair loss after the fourth 
chemotherapy cycle compared with those patients who were randomized to 
chemotherapy without scalp cooling. The trial was stopped early after advice from the 
safety monitoring board because of superiority of hair retention in the participants who 
received scalp cooling. Another publication in 2017 of Rugo et al. also provided evidence 
for less hair loss due to the use of scalp cooling in a prospective cohort study among 
women undergoing non-anthracycline-based adjuvant chemotherapy for early stage 
breast cancer. The results of both studies, lead in 2017 to FDA approval for scalp cooling 
in The United States.(20,21) Since then the use of scalp cooling worldwide has increased 
and the need for improvement of the efficacy of scalp cooling with better selection of 
patients has been emphasized.  
 
FUTURE RESEARCH PERSPECTIVES 
We have shown that shortening the post-infusion cooling time after the administration of 
docetaxel does not negatively influence the outcome of scalp cooling. This is 
advantageous for the patient who can leave the hospital earlier and for the logistics of 
the nursing staff in planning patients for chemotherapy in the outpatient unit. Shortening 
the post-infusion cooling time in other chemotherapy regimens with reasonable scalp 
cooling results would be worthwhile to investigate in future studies. If the outcome is 
positive, it will overcome the disadvantage of a longer stay in the outpatient clinic, since 
we know that this is one of the reasons why not all oncological outpatient clinics offer 
their patients scalp cooling. 
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Adapting the cooling temperature could possibly improve outcomes in a subgroup of 
patients using scalp cooling. This should be one of the areas to explore further in the 
future.  
 
Another interesting area is the use of topicals in combination with scalp cooling. Anagen 
protective agents like ciclosporin or tacrolimus might reduce visible hair loss.(22) 
However, administration of anagen protecting agents is complicated because the effect 
must be limited to the hair-follicle epithelium to avoid favoring intracutaneous micro 
metastasis.(22) Despite this limitation, this is an unexplored area which is interesting to 
investigate.  
 
Improving cap fitting or adapting the scalp cooling technique will probably not lead to 
major improvements of the efficacy of scalp cooling. To move the technology forward and 
improve efficacy, the biological mechanism behind scalp cooling needs to be better 
understood.(23) From rodent and ex-vivo models we know that hair follicle apoptosis 
largely depends on p53, a key mediator of cellular damage caused by a stress 
response.(22) Development of hair follicle research enables direct testing of the 
damaging effects of cytostatic agents in human hair follicles and allows real-time 
assessment of the efficacy of potential preventive treatments.(23) Results of such studies 
could guide our thoughts for larger studies in which for example the addition of topicals 
to scalp cooling can be investigated in a randomized study. To explore molecular 
damage-response pathways in plucked human hair, it is important to select the most 
suitable method. We used the method of Randall et al.(24) Unfortunately, hair follicle 
research is a very delicate process and depends too much on the availability of dedicated 
people. We failed in making a robust model for large scale analysis of hair bulbs. The 
procedure was too time consuming and despite all effort, too much tissue was not 
evaluable. For a better understanding of the working mechanism of CIA, the method as 
described by Randall et al. may not be the best option. Solid methods which consistently 
and reliably can demonstrate molecular damage response pathways are needed. 
Microscopy with Ultraviolet Surface Excitation (MUSE), which produces high-resolution 
images of tissue samples within minutes, could be helpful. 3-D scanning, to visualize the 
entire hair, is another important development which is promising. Hopefully, research in 
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Approximately 30,000 patients start chemotherapy each year (Nederlandse 
Kankerregistratie). Although many side effects of chemotherapy can be controlled, hair 
loss is still a major problem.(1,2) Every year 15,000 patients are at risk for hair loss as a 
result of chemotherapy treatment (Nederlandse Kankerregistratie). To prevent 
chemotherapy induced alopecia, scalp cooling can be used.(3)  
 Unfortunately, scalp cooling is not effective in every patient. A review in The 
Oncologist (Chapter 2) showed that type and dose of chemotherapy are the most 
important factors which can influence the outcome of scalp cooling. The influence of 
patient-related factors (age, gender and hair type) is less convincing or evidence is 
lacking.(4-7) Decreased liver function and menopausal status may also effect the 
outcome of scalp cooling, but so far, there is no convincing evidence.(4-7) 
Gregory et al. carried out a study in 1982 to search for a threshold temperature, 
below which hair preservation was likely.(8) Although this study was performed with 
outdated cooling techniques and a small sample size, it showed that an epicutaneous 
scalp temperature below 19° C was needed for hair preservation. Nowadays, both cooling 
technology and chemotherapy regimens have changed. Therefore, a new study was 
performed to investigate the scalp skin temperature in relation to scalp cooling 
outcomes. Patients with hair preservation had significantly lower scalp skin temperatures 
compared to patients who lost their hair. A precise cutoff point could not be detected, but 
the best results seemed to be obtained when the scalp temperature decreases below 18° 
C (Chapter 3). 
 Cooling time was another important factor that could influence scalp cooling 
outcomes. Scalp cooling is applied before, during and after chemotherapy administration. 
The pre-cooling time was easy to determine. A temperature measurement of the scalp 
skin during scalp cooling showed a temperature plateau after 30 minutes of cooling.(9) 
Determining the best post-infusion cooling time is more complicated. Theoretically, the 
half-life time of cytostatics should be considered. However, there are large differences 
between the half-lives of cytostatics, and the pharmacokinetics show considerable 
interindividual variation. Therefore, the results of different post-cooling times have been 
investigated. (Chapters 4 and 5) In a study investigating a shorter post-infusion 
cooling time, patients treated with docetaxel were randomized between 20 and 45 
minutes after-cooling. The results for both patient groups were similar. (Chapter 4) In 
contrast, in the FEC chemotherapy regimen, a prolonged post-infusion cooling time was 
investigated. In this study, breast cancer patients were randomized between 90 and 150 
minutes post-infusion cooling time. Prolonging the post-infusion cooling time did not 
significantly reduce hair loss. (Chapter 5) 
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 To compare the results of scalp cooling research, it is important to standardize 
hair loss measurements (Chapter 6). Scalp cooling studies report the use of various 
measurement scales. Beside the use of these subjective scales, there also exists a 
method to objectify hair loss with a Hair Check. Therefore, the correlation between 
subjective measurement scales and an objective measurement with the Hair Check to 
measure CIA was investigated in clinical practice. The Hair Check proved to be suitable to 
quantify the amount of hair loss. However, the best method to assess hair loss in clinical 
practice should be the patient’s opinion. 
The molecular damage caused by chemotherapy in hair follicles was also 
investigated (Figure 1) (Chapter 7). It is thought that the mechanism of action is based 
on vasoconstriction and changed cell metabolism, but the exact mechanism is not known. 
 
 
Figure 1. Hair follicle, (a) cross section length, (b) cross section. From: Protection against chemotherapy-
induced alopecia. Wang J, Lu Z, Au JL. 2006 Pharm Res.Nov;23(11):2505-14. 
 
Unfortunately, hair follicle research turned out to be a very delicate process. Better and 
standardized techniques are needed to study the damaging effects of cytostatic agents 
and to test new potential interventions for hair loss prevention.  
 
Conclusion and future 
The Netherlands have made considerable progress in improving scalp cooling and 
worldwide there is also more attention. Scalp cooling research has provided important 
implications for clinical practice and there are many opportunities for improvement. 
Future research should primarily focus on explaining the working mechanism at a 
molecular level and on individualizing scalp cooling: Would it be possible to easily 
measure the scalp skin temperature of the scalp during scalp cooling? Would it be 
possible to identify patients who will benefit from scalp cooling? And additional research 
to reduce the post-infusion scalp cooling time: Would it be possible to reduce the post-
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infusion scalp cooling time for all types of chemotherapy to 20 minutes? Or could scalp 
cooling perhaps even be stopped immediately after chemotherapy administration? It is 
important to improve scalp cooling outcomes and to minimize the burden for the patient. 
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Jaarlijks starten ongeveer 30.000 patiënten met chemotherapie (Nederlandse 
kankerregistratie). Hoewel de bijwerkingen van chemotherapie steeds beter worden 
ondervangen, is haaruitval nog steeds een groot probleem.(1,2) Ieder jaar lopen 15.000 
patiënten het risico hun haar te verliezen door chemotherapie (Nederlandse 
Kankerregistratie). Om haaruitval ten gevolge van de behandeling met chemotherapie te 
voorkomen kan hoofdhuidkoeling worden toegepast.(3)  
Helaas werkt hoofdhuidkoeling niet bij iedereen. Een review in The Oncologist 
(hoofdstuk 2) liet zien dat type en dosering van chemotherapie de belangrijkste 
factoren zijn voor het effect van hoofdhuidkoeling. De invloed van allerlei patiënt 
gebonden factoren (leeftijd, geslacht en haartype) is minder overtuigend of ontbreekt.(4-
7) Verminderde leverfunctie en menopausale status zouden mogelijk ook van invloed 
kunnen zijn op het effect van hoofdhuidkoeling, maar ook hiervoor is nog geen 
overtuigend bewijs geleverd.(4-7).  
In 1982 verrichtten Gregory et al. onderzoek naar een mogelijk omslagpunt in 
temperatuur, waaronder hoofdhuidkoeling het beste werkt en waarboven niet.(8) Hoewel 
dit onderzoek werd uitgevoerd met verouderde koeltechnieken en een kleine steekproef, 
toonde dit onderzoek aan dat een epicutane hoofdhuidtemperatuur lager dan 19°C nodig 
was om het haar te behouden. Inmiddels zijn zowel de koeltechniek als de 
chemotherapie veranderd. Daarom werd opnieuw onderzoek verricht naar de 
hoofdhuidtemperatuur in relatie tot het effect van hoofdhuidkoeling. Patiënten van wie 
het haar behouden werd, bleken een significant lagere hoofdhuidtemperatuur te bereiken 
in vergelijking met patiënten die kaal werden. Er kon geen exacte omslagtemperatuur 
bepaald worden, maar de beste resultaten leken bereikt te worden met een temperatuur 
lager dan 18°C (hoofdstuk 3). 
Een andere belangrijke factor die van invloed kon zijn op het effect van 
hoofdhuidkoeling was de koeltijd. Hoofdhuidkoeling wordt toegepast door voor, tijdens en 
na de toediening van chemotherapie een koelkap op het hoofd te plaatsen. De periode 
van voor-en nakoelen impliceert dat de patiënt langer op de dagbehandeling moet 
verblijven, wat zowel van de patiënt als van het ziekenhuis bij elke kuur een extra 
inspanning vergt. De voorkoeltijd was eenvoudig te bepalen. Een temperatuurmeting van 
de hoofdhuid tijdens hoofdhuidkoeling toonde na 30 minuten koelen een 
temperatuurplateau, waarna de temperatuur niet verder daalde.(9) Het bepalen van de 
optimale nakoeltijd is ingewikkelder. Theoretisch moet hierbij rekening gehouden worden 
met de halfwaardetijd van het cytostaticum. Er bestaan echter grote verschillen tussen 
de halfwaardetijden van cytostatica, maar ook tussen de farmacokinetiek van 
verschillende patiënten waardoor deze aanname toch minder waarschijnlijk is. Daarom 
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zijn de resultaten van verschillende nakoeltijden onderzocht. (Hoofdstuk 4 en 5) In een 
studie naar het verkorten van de nakoeltijd werden patiënten die behandeld werden met 
docetaxel gerandomiseerd tussen 20 en 45 minuten nakoeltijd. Analyse van de resultaten 
toonde een vergelijkbaar percentage patiënten dat geen gebruik hoefde te maken van 
een pruik. (Hoofdstuk 4) Wegens minder goede effecten van hoofdhuidkoeling bij FEC-
chemotherapie werd bij deze soort chemotherapie juist onderzocht of het verlengen van 
de nakoeltijd van 90 naar 150 min een beter effect zou hebben. In dit onderzoek werden 
patiënten met borstkanker gerandomiseerd tussen 90 en 150 minuten nakoelen. Een 
verlenging van de nakoeltijd leidde echter niet tot een significante vermindering van 
haarverlies. (Hoofdstuk 5). 
Om de resultaten van onderzoek naar hoofdhuidkoeling goed te kunnen 
vergelijken is het belangrijk om haaruitval op een eenduidige manier vast te leggen 
(hoofdstuk 6). In de diverse onderzoeken naar hoofdhuidkoeling zijn de resultaten altijd 
subjectief vastgelegd door middel van uiteenlopende meetschalen. Er bestaat inmiddels 
ook een methode om haaruitval objectief vast te leggen met behulp van een trichometer. 
Daarom is onderzoek verricht naar de correlatie tussen subjectieve meetschalen en een 
objectieve meting met de Hair Check om CIA in de klinische praktijk te meten. De hair 
Check bleek een goede methode om de hoeveelheid haarverlies objectief vast te leggen. 
De mening van de patiënt zal echter altijd leidend moeten zijn bij de evaluatie van 
haarverlies in de klinische praktijk. 
Er is ook onderzoek verricht naar de precieze werking van hoofdhuidkoeling 
(hoofdstuk 7). Want hoewel we denken dat het werkingsmechanisme berust op 
vasoconstrictie en het verlagen van het cel metabolisme, is het exacte 
werkingsmechanisme nog niet bekend. Er werd onderzoek verricht naar de moleculaire 




Figuur 1. Haar follikel, (a) lengte doorsnede, (b) dwarsdoorsnede. Uit Protection against chemotherapy-
induced alopecia. Wang J, Lu Z, Au JL. 2006 Pharm Res.Nov;23(11):2505-14. 
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Helaas bleek de methode nog te fragiel. Er zijn betere en gestandaardiseerde technieken 
nodig om onderzoek op haarfollikels van patiënten te verrichten. Hoewel aanvullend 
onderzoek nodig is, speelt dit type onderzoek een belangrijke rol in toekomstig 
onderzoek naar de verbetering van hoofdhuidkoeling. Pas als het exacte 
werkingsmechanisme bekend is, kan onderzoek gerichter worden uitgevoerd en kan 
hoofdhuidkoeling meer worden toegespitst op de individuele patiënt. 
 
Conclusie en toekomst 
In Nederland is de afgelopen jaren een enorme vooruitgang geboekt in de verbetering 
van hoofdhuidkoeling en ook wereldwijd komt er steeds meer aandacht voor. Er is 
belangrijk onderzoek verricht en er zijn nog veel mogelijkheden voor verdere 
verbetering. Toekomstig onderzoek zou zich vooral moeten richten op het verklaren van 
het werkingsmechanisme op moleculair niveau en op het individualiseren van 
hoofdhuidkoeling: Hoe kan de temperatuur van de hoofdhuid tijdens hoofdhuidkoeling 
eenvoudig gemeten worden? Hoe kunnen patiënten geïdentificeerd worden die wel of 
juist geen baat hebben bij hoofdhuidkoeling? Maar ook aanvullend onderzoek naar het 
verkorten van de nakoeltijd: Kan de nakoeltijd voor alle soorten chemotherapie verkort 
worden naar 20 minuten? Kan hoofdhuidkoeling misschien zelfs direct na het inlopen van 
de chemotherapie gestopt worden? Het is belangrijk om de effectiviteit van 
hoofdhuidkoeling verder te verbeteren en de belasting voor de patiënt laag te houden. 
Registratie van gegevens blijft van belang, omdat de behandeling met chemotherapie 
voortdurend verandert.  
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